Time to disrupt the BTK party!
The headline for today’s post reflects a mix of forward looking optimism with some (hopefully)…
A look at the breast cancer data for 3 rising early stage compounds
The evolving CAR-T cell therapy landscape in relapsed/refractory multiple myeloma
An increasingly competitive niche is beginning to shake out in early and late stage disease
A rapid evolving field creates challenges for those following the leaders since the SOC can change quickly
The follicular lymphoma niche is changing and becoming more complex
In the fiercely competitive race to develop new treatments for metastatic castrate resistant prostate…
Bispecifics galore! Finding new ways to raise the bar in aggresive lymphomas and myeloma
A review of 14 early stage developments coming soon at ASH24
Are we searching for treasure and seeing a mirage?
As oncology products are flocking to autoimmune diseases, how is the landscape evolving?
Three ways of tackling PD-1 resistance with different modalities plus an emerging biomarker of response
The route to success is often a winding track with unexpected obstacles
When the future of ADCs and bispecifics collide
What's hot amongst the up and coming CAR-T cell therapies in early development?
Will 2024 be a 'Zeitenwende' moment for the IO field..
Small molecule and ADC standouts – a guest post
How to stand out from the early-stage competition
Challenges and opportunities go hand in hand with early drug development
Is casdatifan the best in class HIF2α inhibitor?
Which Thunderbirds are Go in this niche?!
Things seen in the mirror may be nearer than you think
Going beyond gene edited CARs
The best marketing cannot solve a major product weakness in your compound
How some novel combos may be ones to watch out for
A smorgasbord of bispecifics and CAR-T cells for autoimmune diseases
Reflections on how to overcome hurdles associated with CAR-T cell resistance
On shiny lures and rose tinted glasses blinding reality
A busy and long weekend of data at ESMO24!
Which early stage onco developments are breathing fire and setting the room alike?
As regimens become more complex, so too do other implications
For all the breathless hype and attention focused on antibody-drug conjugates (ADCs) of late, you might…
When everyone zigs – zag!
Red and green flags to watch out for in relapsed SCLC
Why do different agents with the same targets not perform with the same results in the clinic?
On biomarkers, acquired resistance and immune escape, oh my!
7 early stage developments to watch out for at ESMO24
What can we learn from the initial LBA abstract titles?
Why what we don't know might kill a few cancer programs
Finding targets for combinatorial therapy to combat cancer resistance
Are there hideen treasures in Yokohama, Japan
Which combinations make rational sense and which might see action in the clinic?
Not all ADC paths are paved with gold
There's a fine line between success and failure in early stage iO
The good, the bad and the ughly from ESMO24
A detailed look through the window at ESMO24
Some truly novel approaches to tackling advanced cancers
Does the data offer hope for PDAC patients or another case of breathless hype
A look atfive recent developments and what we can learn from them
RAS(on) inhibitors claim to be better than selective RAS(off) inhibitors, but are they just different...
Where is the ADC space heading and waht issues need to be addressed?
Early stage oncology new product development is a rather strange beast at times. On the one hand is the…
When switching therapy areas things can get interesting in unexpected ways...
How pivoting therapy areas might make a real impact for several refractory diseases
Finding the sweet spot between safety and activity
Where to pivot next? That's the question...
Can bicyclic toxin and radio conjuates do a better job than ADCs and RLTs?
Who's going to be roaring forward?
Are the wheels falling off some of the early stage wagons already?
Five trials with an eye for opening minds in entirely different ways!
Interpreting some of the early trails reading out at ASCO24
When the going gets tough, get wacky...
How to beat imatinib and 2nd Gen TKIs
Teasing out relevant markers and learning more about what patients tumours are telling us is key
It's time to challenge our thinking on cytokines
When CAR-T and bispecifics create a crowded competitive landscape
When resistance and toxicities collide, the inevitable fallout is more likely
What's looking interesting in early stage trials at ASCO24?
There has been quite a movement of late in focusing on active treatment of early stage disease rather…
Will new developments in tackling cytokines fare better in the clinic than the first generation attempts?
Will degrading BTK work – even in patients who received prior inhibitor therapy?
Can a new generation of bispecifics change our mind about a particular target?
Switching focus in the critical KRAS pocket
Segueing between preclinical and clinical data
Next generation agents or a new drug class?
In beast mode – or not?
Where epigenetics and synthetic lethality converge
How protecting both the on and the blindside may delay resistance and improve outcomes
The AACR annual meeting is an opportunity to challenge established paradigms and scientific dogma. In…
How kicking things up a notch by thinking outside the box may pay dividends
Finding solutions for tough to drug targets
Sometimes oncology new product development can be fascinating to watch from the sidelines. There are…
An emerging research tool to watch out for in oncology new product development
A vertical and horizontal fishing expedition in new product development
Our 7th AACR Preview takes stock of an emerging class of anti-cancer agents
In 2011 we did an annual ASCO highlight video reel of what to watch out for. Three phase 1…
In our fifth preview from the AACR annual meeting being held in San Diego next month, we noticed some…
The good, the bad, and the ugly under belly of the next flurry of ADCs
W2W4 - what to watch for in an emerging oncology niche
Do not feed the alligators is a common sign seen in the hammock areas of Florida where brackish fresh…
Finding nuance and solutions amongst the clutter
What happens when multiple oncogenic pathways converge at the crossroads? An important aspect to watch out for heading into AACR24
Targeted therapies are still going strong in 2024 – here's an example of a rational combination approach being developed in the clinic
Homing on new opportunities for an old drug class of targeted agents
Finding the right cell/right compartment isn't easy - it requires persistence and dedication
Does a trial readout stand up under the microscope
Where we look at half a dozen emerging agents and put them through their paces
An early stage landscape to watch out for with key changes happening in 2024
It's time to start pointing the way for new directions in the Menin niche
Dark storm cloud warning from a small cap biotech
A twist in the ADC moiety to think about
Our take on data from half a dozen key trials at ASCO GI24
A look at an emerging early stage product which is looking intriguing
It's time to look to the future beyond plain vanilla ADCs
Winners and losers at JPM24
Next generation CAR-T cells are coming to the clinic in 2024
Improving T cell fitness is an important goal for researchers in 2024
It's beginning to look a lot like Christmas...
Hats off to companies pursuing an emerging target in breast cancer
The Yin and Yang of NK and T cells and how this can impact therapies
What was generating interest from Pharmaland in the ASH poster halls?
What to watch for in emerging CAR-T cell therapy approaches and how they may give antibodies a run for their money
Important lessons learned from failure
10 IO topics to watch out for at ASH23
In our latest Preview from the American Society of Hematology, we’re using the dragon’s…
How a competitive landscape can change drastically over a short time
What's next beyond BTK inhibition in lymphomas and CLL?
Pulling disparate sources together to develop a more optimised approach to targeting oncoproteins
There is beauty in drugging intractable targets
A look at the potential missing piece in making bispecifics even better
Spotting the winners and losers in the gastric cancer niche
W2W4 at SITC23 - 10 emerging areas to pay attention to in IO
Some up and coming novel ADCs to watch out for
Will in vivo CAR-T cell therapies go prime time?
Eight key areas to watch out for at SITC 2023!
Out of the ashes, a new phoenix can rise
Dawn of a new IO era at ESMO23?
Red and green flags on certain trials at ESMO23
After a long wait, finally some encouraging data in advanced solid tumours!
Important new findings on the cell therapy front
8 targets to watch out for at ESMO23
More gems from the TARGETS23 poster halls
Searching for well tolerated combinations in the KRAS niche
From small acorns, so oak trees grow
What to watch out for in DDR, epigenetic therapies, and other hot topics
From epigenetics to SHP2, a look at various upcoming presentations this month
There's a huge surge in ADCs in the clinic but how many will make an impact?
Parsing cancer research hype at ESMO23
A look at some hot topics from the TARGETS/TRIPLE meeting in Boston
From CAR-T cells to protein degradation
What we can learn from scientific talks at WCLC in order to improve clinical development
Review of new KRAS inhibitor studies including G12C and G12D
Seeing the wood from the trees in ES-SCLC developments
Early-stage agents in development for multiple myeloma - hit or miss?
Do we need to pay more attention to the underlying biology in aggressive lymphomas?
Challenges and opportunities in the myeloma niche
Important new preclinical data sets the scene for PDAC
As we head into the long August Bank Holiday and Labor Day celebrations, I wanted to offer some…
Part 2 of our WCLC 2023 Previews
Finding the sweetspot in early stage cancer drug development
How exploratory new biomarkers are paving the way
One of the challenging and frustrating aspects of oncology drug development is in knowing a target is…
Some perspectives on the balancing act required between stimulus and response
Progress report on a varied China based CAR-T cell program
When an established concept is finally coming of age with new colours...
Taking a different approach to CAR design with some positive data to show for it
Preview - Wwat to watch for at WCLC23
Highlighting some outstanding research to take note of
Have we reached the point where Pharmaland cooks the golden goose?
Finding rare thistles in the fields
How we can use AI to improve scientific writing and reports
A potentially novel approach for some advanced breast cancers
Where a forgotten costimulator may hold the key to new developments
Encouraging new developments in the CAR-NK niche
From autologous to gene edited CARs and much in between - W2W4 on 14 next gen products
There's much more to think about implications from readouts than the scoreboard
New developments in hard to treat refractory PTCL
We put 10 clinical trials through their paces to ascertain whether they were hype or not
Tackling intractable cancers with a novel and creative approach to the problem
Continuing our coverage of the annual meeting of ASCO in Chicago I felt compelled to review the actual…
What do three phase 1 and one phase 2 trials tell us about future development?
A look at 4 trials with largely unexpected results
Highlights from Day 1 at ASCO23
How does the NATALEE trial stack up in adjuvant HR+/HER2- breast cancer?
Novel KRAS developments to watch out for
Some ASCO23 abstracts to watch out for and why
Opportunities and challenges abund for several next-gen CAR-T cell therapies
Next generation CAR-T cell therapies for solid tumours
A discussion of some of the key topics emerging in ER+ HER2- breast cancer
Have you ever wondered why some anti-cancer agents do well and others poorly – even with similar…
A next generation category of KRAS inhibitors are emerging - W2W4
What's new on the CAR-T cell therapy front?
Off the beaten track can bring danger and delight in the unknown in equal measure
Update on Developmental Therapeutics
Where we explain what to look for in 10 posters presented at AACR23
A look at some early stage ADC molecules in the clinic
Orlando – At AACR23 the old adage of “be the first, or be the best” is well and truly…
Initial learnings on KRAS presentations at AACR23
W2W4 on the TPD front
From one compound to many competitors following in their wake!
The ever evolving selective KRAS inhibitor & degrader space
A look at an emerging early stage oncology landscape
Continuing our evaluation and exploration of another batch of early stage anti-cancer compounds either…
As we continue our new products journey evaluating early stage agents in development with data at…
Early stage new product development part 1 - seeing the wood from the trees
Half a dozen key early areas to watch out for
In a few years time the next generation CAR-T cell therapies are going to look and behave very…
It’s all too easy to think of New Jersey as the behemoth of Pharmaland in the north east, while…
Improving cell therapy performance with a multitude of innovative strategies
Key developments which could kickstart a renaissance for CAR-T cells in solid tumours
A look at some new developments in CAR-T cell therapy for gliomas
We have heard much over the last decade or so about the impact of the microbiome on responses to…
The next generation of CAR-T cell therapy will require out of the box thinking
How the landscape in prostate cancer could change in the medium to long term
How base editing can transform the development of next gen CAR-T cell therapies
Some promising new early developments are coming through in AML and T-ALL - what's the skinny?
A rising area of interest in the CAR-T cell space
What will be the emerging products and regimens to watch out for in aggressive lymphomas?
Going beyond the first past the post syndrome...
A novel approach to targeting an intractable oncogene
An in-depth look at what's behind an upcoming milestone
How can performance of T cell therapy be improved?
The evolving BMS-Celgene pipeline and what's coming next in new developmental twists
How novel bispecifics might help potentiate the impact of KRAS inhibitors when combined with checkpoint blockade
How can we overcome immune escape in relation to TIGIT therapies?
Ten emerging development areas to watch out for in oncology during 2023
A deeper look at the ARC-7 TIGIT readout
A look at an evolving niche in hematologic malignancies
Some key subtleties and nuances to watch out for in the Menin niche
A hard look at the KRYSTAL-7 data presented at ESMO IO
The importance of T cell exhaustion and exploring ways to avoid it
10 early stage IO biotechs to watch out for
The beat goes on for synthetic lethal approaches
A look at how changes in antibody design can make a potential difference
Half a dozen key posters to watch out for in early stage oncology at SITC22
What started out as a short update from the recent EORTC-NCI-AACR (ENA / Triple Meeting) in Barcelona on…
Reprogramming T cell phenotype is becoming a hot topic in solid tumours and here's why...
Beyond KRAS - targeting another of the four horsemen of the apocalypse
Biomarker highlights to watch out for at SITC22
Are there opportunities for combining small molecule inhibitors with protein degraders?
Five areas of early stage IO developments to watch out for
6 abstracts to watch out for on how to overcome immune escape
Can we overcome resistance checkpoint blockade with novel approaches to DDR?
Where is the TPD field likely headed with next generation approaches?
Bispecifics come and bispecifics go as companies seek to find a balance
What really stood out from the oral presentations at ESMO this year?
An in-depth look at some of the issues impacting Amgen's pivotal trial and what it means for their competitors
How do we help more early stage ccRCC patients live long and prosper?
Round up ad discussion of key breast cancer trials in HR+/HER2- disease
Are all PARP inhibitors the same?
New developments in early stage targeted therapy agents
In our latest ESMO conference preview it’s time to pick some early stage immunotherapy highlights…
What to watch out for in colorectal cancer, cholangiocarcinoma and hepatocellular carcinoma
Review of some of the key trials in breast cancer being showcased in Paris next month
A look at promising new approaches in SCLC
On fast followers and novel G12C combinations
Trials and tribulations associated with KRAS plus IO combos
6 important and encouraging new developments to watch out for
Interview with Dr Vipin Suri, CSO Catamaran Bio about the science behind their CAR-NK cell therapy.
Going beyond small molecule inhibitors to degrading various intractable targets
A rock around the KRAS clock
First in a mini-series featuring some of the companies that presented CAR-NK cell data at AACR22
An emerging new and highly selective oncogenic target
What can we learn from IO trials in lung cancer to help us evaluate TIGIT's prospects?
Exploring future IO-IO combination strategies and life cycle management
Where five different targeted therapies are put through their paces
There’s always a parable or two to be had at ASCO and this year was no different, especially in…
The continuous evolution of BCMA CAR-T cell therapy products and how they are doing
A look at early stage CAR-T cell therapies in development
When cell therapies and targeted therapies collide
Five key areas to watch out for at ASCO22
What can we learn from the data on inhibitory checkpoints not named PD(L)1 or TIGIT?
What can we learn from a raft of early cell therapy companies with novel or intriguing approaches?
What's the skinny on C4 Therapeutics and other TPD programs at AACR and ASCO?
Six important factors to consider when looking at the SKYSCRAPER-01 TIGIT readout
Hot or not - 5 early stage trials with different agents and targets
5 abstracts to watch out for at the ASCO22 meeting in Chicago
Can NK cells help checkpoint blockade work more effectively?
New CAR-T cell developments in solid tumours - hit or miss?
Looking beyond the hype from a broader perspective
5 key and novel early areas of development which stood out to us at AACR22
Going beyond both G12C and G12D to a plethora of new targets and combination approaches
All aboard to hear more about novel targeted therapy combination strategies...
Finding new synthetic lethal targets to induce more potent cell death and improve outcomes
A lion roar or whimper at the prospect of KRASi plus IO trials?
Everything you needed to know about bispecifics at AACR22 and more!
What to watch out for at AACR22 if you're interested in NK cells
5 areas to watch out for on the bispecific antibody front
Can you have your immune cake and eat it?
A look at subtleties behind the PEARLS trial in adjuvant NSCLC
Is the OlympiA trial groundbreaking for early stage breast cancer?
Just because a pathway has been called undruggable doesn't always mean it will be so!
The latest on bispecifics and protein degraders
Hot topics to follow at AACR22
Can a different twist on modality make a real difference and go beyond what we already have?
Some important new research which may stimulate a whole new class of anti-cancer therapies
The battle over AR antagonists and degraders rages on as new clinical data emerge
Surprises galore in the unveiling of the PARP data in 1L mCRPC!
Trick or treat? A look at the sotorasib data in PDAC.
An important phase 3 readout to mull over - what's not to like?
CAR-T cells have struggled to make an impact in solid tumours, are things changing for the better?
A look at new and quite unexpected directions for CAR-T cell therapy
Highlights from Day 1 CART22 Part 2
Highlights from Day 1 of CART22, part 1
Some important new papers on CAR-T cell therapies are shedding light on potential new combination strategies
Cracking the tumour code
A look at an early potential oncogene target in liquid and solid tumours
A look at some recent phase 2 data in the KRAS niche in the context of the broader landscape
A careful look at the latest anti-TIGIT data
Exploring new approaches to targeting cancer
Preview of what to watch out for at ASCO GI22
It's time for an update on novel protein degraders
Can we improve the quality of T cells performance and boost outcomes?
The intriguing science behind a novel protein degrader platform
What to watch out for in 2022
Be more dog!
9 hidden Gems from the ASH21 poster hall and why you should pay attention to them
A look at a major phase 3 trial result and some of the nuances behind the data leading to a negative study
Part 2 of our mini-series on Next Generation CAR-T cells
Overcoming the limitations associated with CAR-T performance and lack of persistence
A look at some combination IO strategies in early clinical development to watch out for
What can we learn from various breast cancer trials?
Several controversies abound in the CAR-T cell niche this year, plus what's coming next?
A dozen early stage biotechs in the RAS/RAF pathway to watch out for
Novel approaches to fine tuning CAR-T cell therapies are hitting the clinic
Sometimes we learn more from failure than we do from success
A number of new developments to consider in the KRAS niche
With SITC fast coming up this week, immunotherapies in all sorts of shapes and guises are very much…
Update on the various runners and riders in the TIGIT niche
A look at the sheer breadth and depth of bispecific approaches from a myriad of different biotechs
SITC 2021 Preview
A detailed look at Repare's ATR inhibitor data from the TRIPLE meeting
Where next in the ever expanding KRAS runners and riders?
Will Relay's FGFR2 live up to expectations?
It’s time to look at progress on the ADC front, something we sporadically cover where there are new…
What can we learn from KRASi combinations? Do any stand out?
Key learnings and highlights from the recent AACR DLBCL specialist meeting
One of the things that struck me at this year’s ESMO conference was the sheer variety and richness…
A deep dive into the phase 2 COAST study, along with some expert anecdotes
Developmental Therapeutics is hard, how do companies go about finding a way forward?
A look at the controversial adagrasib data in mCRC at ESMO21
A practice changing trial of note at ESMO21
A hard look at some IO agents in early development at ESMO21
Key posters of interest at ESMO21
Highlights from WCLC Day 1
A look at some cool science and novel strategies for tackling an intractable target
Can a genomic signature help select patients more accurately for DDR therapies?
What's hot at WCLC21?
It's time to tackle some intractable targets in oncology and elsewhere...
Is it a marker or a target? Actually, what is the target - and why does it matter?
What are Novartis up to these days with their oncology pipeline and what are they excited about?
A look at why and how Relay's early oncology pipeline might be one to reckon with
What are Gritstone up to behind the scenes and where are they headed in the near-term?
Can AI and deep learning help us re-program genetic defects with RNA therapies?
What can deep learning techniques tell us about NASH, Parkinson's, Alzheimer's or even cancer?
Update on the T cell engager niche with an emerging agent of interest
A careful look at what we can learn from the Beigene anti-TIGIT data for ociperlimab
Update on C4, Kymera, Novartis and Vividion
Do we need to target the adenosine fog as well as TIGIT in NSCLC?
Continuing our ongoing series on immunosuppression and finding ways to overcome the hostile TME
Round-up of key highlights relating to CAR-T cell therapies, CELMoDs and super-enhancer activity in DLBCL
A look at two under the radar early developments in lymphomas which might have a shot at approval
How can AI and ML speed up or improve our drug discovery efforts in oncology R&D?
A look at 6 IO products in the Heme space and what to watch out for.
Update on the Novartis SHP2 inhibitor at ASCO21
New product development and early phase anti-cancer agents have been very much a focus on BSB (and PSB…
A look at what's happening in RCC and what to watch out for at ASCO this year
PARP inhibitors move into the adjuvant setting at long last? Say it ain't so!
A look at the first anti-cancer therapy with a radiopharmaceutical in advanced prostate cancer
Who's going to the masquerade ball and how might they fare in the future?
A look at some hidden gems in the ASCO program and what it all means in terms of the science.
Hidden early stage gems to watch out for at ASCO21
Which abstracts stood out in the initial run through of the data? Includes some hidden gems and surprises!
Going beyond the obvious conclusion with anti-LAG3 therapy
New developments on the KRAS and SHP2 front
New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.
Some key learnings from the ESMO Breast Cancer meeting held last week
Bridging the DDR gap from AACR to ASCO
Who's going to win in the battle between protein degraders and small molecule inhibitors?
What can we learn from C4 Therapeutics monoDAC, CFT7455?
A look at the subtleties and nuances under the hood of the Arvinas PROTACs
13 ways in which CAR based or gene therapies can improve on current approaches to cell therapies
A look at new data in the Menin/MLLr inhibitor landscape in acute leukemias
A look at switchable CAR-T cell therapies, plus CARs based on alternative immune cells.
13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?
A rock around the bispecific clock highlighting key presentations coming at the AACR 2021 virtual meeting
What's hot in early preclinical development to watch out for?
A look at a potential emerging target which could be druggable
What's hot on the DDR front and PARP inhibitor space at AACR21?
Emerging areas in cool new science around targeted therapies
Combinations will be the future for KRAS inhibitors but which ones and why? Includes some new ideas!
Capturing attention in the crowded protein degradation niche
What to watch out for in the protein degradation niche
Getting to the centre of things with protein degradation
Degrading oncogenic proteins with novel bacterial approaches
How prodrug technology can lead to improved delivery of potent chemotherapy in select tumour types
A novel approach to chemistry can potentially transform a therapeutic modality against cancer
How do we unleash more cytotoxic T cells against a cancer with a high unmet medical need?
Will the eganelisib data be positive in TNBC from the MARIO-3 trial?
What's under the hood with a personalised cancer vaccine? Quite a lot it seems!
Gems from the WCLC20 poster hall which may make an impact
A look at the exon 20 insertion landscape - all to play for!
Genomic analysis in IO trials is on the increase - what happens when PD-1 and KRAS collide?
Discussion of the Amgen sotorasib data presented at WCLC20 in Singapore
Some intriguing convergence from two recent conferences offers new insights from an AI perspective
Exploring a novel approach to overcoming immunotherapy resistance
A novel IO target with a chequered history is starting to look more promising - which one and why?
Important developments on the GI cancer front to watch out for
A rock around the myeloma clock through the eyes of a KOL - what stood out and what did not?
Beyond CAR-T cell therapy there are novel bispecifics coming along so where and how will they fit in?
A look at what we can learn from the cilta-cel BCMA CAR-T cell therapy data and where things are likely headed
A critical look at the early stage BMS oncology pipeline
Commentary on engineered NK cells, including CAR-NK and memory-like NK cells
Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?
What's worth following on the targeted therapy front in breast cancer? A look pipelines and new indications from SABCS
Post SABCS analysis of a key topic and cancer driver
It's time to turn our attention to novel TKI approaches in hematologic malignancies
What caught our attention on novel bispecific antibodies at ASH20?
Highlights on translational research and clinical trials in AML and BCLA CAR T cell therapy
Commentary on Saturday at ASH20
W2W4 in targeted therapies at ASH20 - some key early stage areas to focus on
New developments in the BTK niche offer fresh insights on progress
Rock around the CAR-T cell clock to learn what to watch out for at ASH20!
Oncogenes and tumour suppressors can have surprising effects on targeted therapies and immunotherapies
A look at several different innate immune system approaches
What's hot on the antibody and ADC front at ASH 2020?
Updated look at the bispecific landscape in early clinical development
new approaches to applying translational research to the clinic in oncology R&D
We still need to kill cancer cells to get durable complete responses - a look at ways to accomplish this feat
The devil is in the finer details...
It’s time to look at the latest update on KRAS mutation specific agents in clinical development as…
The trials and tribulations of targeted agents in developmental therapeutics
Science drives oncology new product development and the AACR special conferences are always a good place…
How we can learn more from failure in clinical trials so we can improve outcomes further with emerging agents in early development
An update on two very different targets in the broader KRAS niche, one of which may have a particularly long lasting impact on the landscape.
How early evolutionary changes in cancer can impact hot/cold regions and patient outcomes
Winners, losers and risers... who goes where in the final analysis?
Rising stars become supernovas or disappear into a black hole of R&D - a look at what we can learn from one company's early stage compounds
Commentary on data presented at ESMO20 for PIONeeR Lung Cancer Immunotherapy Project
A look at one oncology biotech company's early pipeline and how it fits in with the emerging landscape
Surprising new developments in early stage breast and metastatic prostate cancers
Reflections on data in early breast cancer and NSCLC presented on Sunday at #ESMO20
Solid tumour highlights from ESMO not including breast cancer
Breast cancer highlights from Saturday at ESMO20
Commentary on Day 1 at ESMO20 and data presented in the mini oral sessions
What to watch out for this weekend in targeted therapies and early stage new product development
Five IO areas in early stage development to watch out for at ESMO20
Can we predict the future cancer drug combinations from emerging new targets?
A look at progress and new developments in cancer biomarker developments
Novel approaches to metabolism may have far-reaching effects on anti-cancer therapies
Using CRISPR screens to find new targets for enhancing T cell fitness
Some intriguing new developments in DLBCL to watch out for
How can we use metabolic reprogramming to enhance CAR T cell therapy?
Rare mutations in lung cancer (STK11/KEAP1) could be associated with defects in cancer metabolism - we look how they impact KRAS mutant lung cancer
Can we influence T cell fitness and performance by manipulating metabolic processes?
Today’s focus is on an emerging new biotech company with potential to make an impact in difficult to…
In this post we’re taking a look at what we learnt about immunometabolism at AACR20 and some of the early signals from a cancer new product development perspective.
The aim of this post is to give you a sense of the potential of immunometabolism to impact T cell fate, fitness, and function.
What can we understand from novel research on the biology of the disease that might lead us to new cancer therapeutics?
A new emerging IO target of interest caught out attention, now what?
A novel epigenetic target may have far-reaching outcomes for cancer patients
A look at Kymera's protein degrader pipeline
Was the ODAC hearing a win or loss in the GSK vs FDA battle for the first BCMA approval?
George Martin’s quote seems rather apt this morning as NextCure announced there was disappointing…
If we were to tackle CAR T cell therapy design differently, how would we go about doing it?
The ups and downs of CAR-T cell therapy development continues apace
Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...
Update on the Gamma Delta T cell niche - what's new, what's up, and what's down?
Will we have more success targeting IL-18 to boost anti-tumour immunoty than other cytokines?
A look at some novel and promising approaches in early oncology new product development
Looking under the hood in NSCLC at underlying mutations and whether or not they impact survival
What can we learn from the recent announcements for lurbinectedin in 2L SCLC and the CDK4/6 inhibitors in adjuvant HR+HER2- early breast cancer.
An update on the CD20 x CD3 bispecific with expert commentary on data at ASCO EHA.
There's a wealth of clinical and biomarker data to explore in RCC, which may have implications for prescribing changes in the near future
Highlights from several solid tumour trials in both early and late stage disease.
Which hematology products in development produced the best data at ASCO 2020? We took a look at the key studies in lymphomas and myelomas to find out.
Highlights from various breast cancer trials and new pipeline developments
A look at Genentech's tiragolumab (anti-TIGIT) in advanced lung cancer
Dr Ross Camidge provides a critical review of ADAURA trial of osimertinib in adjuvant EGFR mutant lung cancer presented at the 2020 ASCO annual meeting.
From bench to bedside has many twists and turns along the way - an update on a longitudinal story we have been following for 5 years
10 developmental therapeutics abstracts to watch out for at the ASCO 2020 virtual meeting
There are a few new developments of note to consider from ESMO Breast this weekend plus more to come at ASCO20 on Friday
An in-depth look at the emerging SERD landscape in ER+ metastatic breast cancer
Does modality matter in oncology drug development and if so, where?
There are some creative and innovative new CAR T cell therapy designs being developed - what are they and where will they be tested?
Review of 12 posters that caught our attention in the ePoster Hall at ASGCT20
Another fine example of how our understanding of the biology underpinning a certain type of cancer can lead to drugging the undruggable (no, it's not KRAS!)
What do we learn from the initial data with novel PROTAC technology?
Will CAR-NK cells follow CAR-T cell therapies and hit prime time?
A look at what a young up and coming biotech in the TIGIT space are doing and how they see their approach being differentiated from the competition.
A raft of updates on the R&D pipelines in the adenosine niche, plus a biotech company interview
New developments in the DDR niche suggest a whole new approach to tackling solid tumours beyond women's cancers, pancreatic and prostate cancer might be feasible.
A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences
One particular presentation stood out from the others at AACR20 this year
In our latest postcard from AACR20 virtual meeting we take a look at the adoptive cell therapy plenary session
Commentary on Day 1 of the AACR20 Virtual Meeting
Why you should be wary of the hype surrounding the Iovance TIL data in NSCLC at AACR20
Ten intriguing novel agents in early development to watch out for
Beyond KRAS G12C inhibitors, there are plenty of other related targets to consider including KRAS::SOS1 and SHP2
A look at a wide array of targets, modalities, new agents and companies through the lens of targeted therapies
What to watch out for at AACR20 - the first of our meeting previews is here!
A look at the revised schedule and timelines for upcoming Spring cancer conference season
Where are they now four years on? A look at the BET/Bromodomain landscape
Some immune cells overlap in cancer and Covid-19 so what can we learn from them in order to make an impact?
How can we go about improving cell therapy approaches?
When T cells stop working how can we get innate immune cells like NK cells to take up the slack and help track down tumours?
In the first part of the review on novel targets in hematologic malignancies, we covered five key areas…
Tackling immune suppression in hematologic malignancies may improve outcomes with existing regimens
Reprogramming the tumour microenvironment - can it be done and if so, how and what should be targeted?
Can we learn from what a patient's tumour is telling us in terms of what the immune system is responding to in order to target it therapeutically?
Manipulating immune cells in order to harness great antitumour responses to immunotherapy
Key RNA transcription factors may have a role to play as therapeutic targets for both cancer treatment and the coronavirus
An expert interview with a leading immunologist who discusses two translational opportunities with potential for cancer immunotherapy
An interview with Mirati's Chuck Baum and Jamie Christensen exploring the evolving opportunities and challenges in the KRAS G12C niche
Insights from Transplantation & Cellular Therapy (TCT) meeting on the next generation of CAR T cells
Monotherapy approaches won't be enough to shut down KRAS mutations in solid tumours, so what targets can we add in to reduce acquired resistance?
Highlights from ASCO GU 2020 with some interesting targets and emerging molecules to consider
In this post we look at an emerging research area that will be important to address if CAR T cell therapy is to be effective in solid tumours
CAR T cell therapy for solid tumors is the cancer new product development equivalent of the quest for the "Holy Grail."
Interview with Dr Carl June on what the next decade holds for CAR T cells, cell therapy and genome engineering
Interview with Prof John Gribben at second European EHA EBMT CAR T cell therapy meeting in Sitges, Spain
Commentary on Day 2 of the EHA EBMT 2nd European CAR T cell meeting
Commentary on first day of EHA EBMT European CAR T meeting in Sitges, Spain
Can innovative our ability to reinvigorate stalled CAR T cells affected by immune escape from CD19 loss or downregulation of BCMA?
Looking beyond CAR-T cells and checkpoint blockade, there are some promising young companies on the rise to watch out for - here's one of them
A report card on important trial updates across gastric, pancreatic, liver, and colorectal cancers at ASCO GI 2020.
Novel approaches in AML seek to overcome the challenges of the past and improve clinical outcomes.
Overcoming acquired resistance to KRAS inhibitors will be key to success - here's one potential way to do that.
Update on Kura Oncology's progress with tipifarnib and their emerging pipeline
What's in store on the penultimate day of JPM20?
Highlights (and lowlights) from the second day of the JPM Healthcare conference in San Francisco
Highlights and lowlights from Day 1 of JPM20
Following the recent failure of Incyte's itacitinib in acute GVHD, we look at promising early developments following in their wake.
TIM-3 may have a role to play in myeloid hematologic malignancies such as AML and MDS. We explore the scientific rationale, competitive landscape, and initial clinical data.
Six key strategic factors to consider going forward in the quest for future oncology R&D pipelines
Some novel targets, new agents and some twists in the tale to consider in hematologic malignancies
A look at what happened from the DREAMM1 to DREAMM2 trials exploring the BCMA ADC belantamab mafadotin in refractory multiple myeloma and why GSK have a challenge ahead
A look at the KEYNOTE-522 and neoTRIP clinical trials in neoadjuvant TNBC
A look at tucatinib, margetuximab and trastuzumab deruxtecan in HER2+ advanced MBC
A look at some of the highly ranked clinical data presented over the weekend in Orlando
Science Friday at ASH19 with a look at various lymphoma and myeloma developments
A look at new developments in the KRAS niche and also a potential emerging novel target in addressing the development of acquired resistance.
A look at off Broadway abstracts on early new product development and scientific findings of interest
Non-T cell based immunotherapies that could be promising in hematologic malignancies
Some hidden gems and under the radar abstracts that may appeal to the off-Broadway crowd at ASH19
Highlights from SITC 2019 including small cap biotechs with novel or innovative approaches to consider
Analysis and commentary of Nektar's IL-2 cytokine bempeg in combination with nivolumab in 1L advanced melanoma
If we want to improve on the current results with IO therapies then we need to go to basics and understand the biology of each disease subset in the context of what we've learned so far
It's time for an update on new participants to the runners and riders in CLL and NHL. Some interesting findings with BTK inhibitors to consider here!
What's hot at SITC19 this year? We highlight half a dozen key presentations of interest to BSB readers and explain why they matter.
What new things will we learn about the microbiome at SITC19?
How do we improve responses to EGFR, BRAF & KRAS inhibitors? One way may be add in a SHP2 inhibitor - we look at why this target matters and which competitors are in this niche.
KRAS isn't the only RAS mutation seeing progress - there's also HRAS which is now druggable thanks to Kura Oncology's tipifarnib
Dr Pasi Janne presented the initial first-in-man data from Mirati's KRAS G12C inhibitor MRTX849 - what did we learn?
What did we learn at #Targets19 about targeting NRG1 gene fusions with MCLA-128?
On dosing issues, read across from BRAF in CRC, what is SOS1 and a look at future combinations...
How do we go about targeting KRAS mutations beyond G12C? Here's one elegant way that is promising yet very early in which it could be approached...
There are some potential unexpected new pretenders to the Novartis and Kite's CAR-T cell therapies in Europe. We discuss what they are and why they should be taken seriously.
As checkpoint therapies start moving into early stage disease, how do we go about deciding which people to treat? An example using TNBC.
Where are CDK4/6 inhibitors going and are there new opportunities for this class of agents outside of HR+/HER2- breast cancer?
What can we learn from the phase 2 trials with PARP inhibitors in mCRPC? Quite a lot, it would seem...
Insights from a US KOL on the phase 3 PROfound trial exploring olaparib in mCRPC
Highlights from the PROfound trial in advanced prostate cancer and other stories of interest
Key findings and commentary on the third day of ESMO
A look at the FLAURA overall survival results and what we can learn from the phase 3 trial
We saw signs of activity from Amgen's KRAS G12C inhibitor in lung cancer at WCLC so it's time to look at what happens in colorectal cancer.
Review and analysis of key trials presented on the second day at ESMO 2019
Commentary and Insights from Day 1 of ESMO19
Some early stage oncology agents in development that seek to target and tackle inhibitory and immunosuppressive factors
Preview of ESMO19 around targeting DNA damage repair (DDR) for GU cancers.
What should we be watching out for in terms of red and green flags at ESMO on the breast cancer IO front?
WCLC 2019 Review – Part 3 - Targeted Therapy Highlights excluding KRASi
Summary of IO highlights and lowlights from WCLC 2019
Barcelona – Gosh, what a weekend chock full of lung cancer data at the World Congress on Lung Cancer…
Is Siglec-15 a key target in overcoming immunosuppression in some cancer patients?
An initial primer on the emerging area of Siglecs within the glycobiology niche
A look at BET-bromodomain inhibitors, PROTACs, stapled proteins and more on MYC
How do we go about therapeutically targeting deep protein-protein interactions that can cause aberrant cancer activity? Here's one novel approach in early development...
How do mission critical oncogenes cooperate and act in concert in cancer?
If we want to be able to drug oncogenes such as MYC then we need to figure out how they work and function to find the achilles heel
A potential role for epigenetic therapies in straddling the divide between transcription factors and the immune system...
What can we learn about the MYC transcription factor and oncogene in order to turn it into a viable target in oncology R&D?
Latest preclinical and clinical news and readouts as well as forthcoming trial presentations to look forward to in the DDR space
What can we learn from recent trial data exploring a STING agonist in combination with anti-PD-1 in advanced solid tumors including TNBC & melanoma?
Our latest analysis of the ever evolving NSCLC landscape following BMS’s announcement on CheckMate-227
Thoughts and commentary on the Jounce-Celgene collaboration update and the emerging ICOS landscape
A review of our Top 10 sarcoma results from ASCO19 plus commentary from a specialist KOL in this niche
Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?
Insights on the updated phase 1b clinical data evaluating Neon's personalized vaccine NEO-PV-01 in combination with nivolumab in advanced cancers?
What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess
Next generation IO molecules are likely to feature bispecific antibodies - can we address the weaknesses seen with immune agonist antibodies by switching modalities?
We saw a number of challenges emerge with immune agonists as antibodies and now companies are experimenting with them in bispecifics - what needs to be considered to make them work? What will the next wave of IO look like?
Can mRNA disrupt cancer therapy and boost responses beyond what we see with checkpoint therapy?
Is T cell therapy like Game of Thrones?
What can we learn from biomarkers and immune profiling in patients receiving bempeg, a CD122-directed pegylated IL-2 therapy
How is Synthorx's IL-2 cytokine THOR-707 different from other compounds in this niche?
How the design of different cancer approaches can affect clinical performance
Round-up and analysis of key lymphoma data at iCML 2019
Can we employ red blood cells in allogeneic, off-the-shelf cellular therapy products for the treatment of cancer?
Update on PTCL developments and a possible new therapy that may be approved in this setting
New data suggests there may be value in targeting CD73 as well as the A2A receptor in certain tumour types...
Looking under the hood to find biomarkers of response and outcomes, ,
Thoughts on Macrogenics phase 3 SOPHIA trial exploring margetuximab vs. trastuzumab - hit or miss?
On KRAS in lung cancer, HRD in pancreatic cancer (not POLO) and genomics in RCC
A look at some of the hidden gems and struggling compounds in competitive niches at ASCO19
Insights from Day 2 of ASCO19, plus a look at what to expect in the plenary and other sessions today.
A review of some this key data presented including new compounds in early development and how they stack up against existing therapies.
Hidden gems - what to watch out for at ASCO19 off the beaten track amongst the wealth of data to peruse
A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.
Highlights (and lowlights) from Day 2 of immunotherapy presentations at CIMT 2019 in Mainz.
A report from the CIMT 2019 annual meeting exploring key highlights from the presentations on tumour biology and cancer immunotherapy.
Working out which are markers versus valid targets is going to be key in IO progress. Here we look at one particular candidate...
Exploring the many challenges associated with targeting KRASG12C and why we should temper enthusiasm for this niche
A review of the latest available TLR data and a look at an emerging biotech Silverback Therapeutics in this niche
Proteins change shape, both temporally and also in response to different conditions. Can we use this information to develop novel cancer therapeutics? One company is exploring ways of achieving this.
A look at inducing apoptosis of cancer cells via CDK7 inhibition and the future for rational combo approaches.
How next generation immunotoxin approaches can overcome capillary leak syndrome and be effective anti-cancer agents
Gritstone have evolved from start-up biotech to clinical stage oncology company. We catch up with them and discuss their latest progress.
Can gamma delta T cells be effective as a therapeutic in GBM?
Is there a better way to target myeloma than with BCMA alone? Data suggests there's plenty of room for improvement.
A look a the updated adenosine pathway landscape and how it is progressing
As look at ways of targeting 𝞬𝝳 T cells, we may need to consider whether or not the situation is immunosuppressive or proliferative
Neutrophils may be responsible for inducing immunosuppression and resistance to checkpoint therapies so how do we target them in the clinic?
We've heard much about PARP inhibitors but they aren't the only targets in DDR we can hit...
With the help of a leading pathologist, we examine the challenges associated with PD-L1 and TMB as biomarkers for patient selection
Having a companion diagnostic is important for precision medicine, but can they accurately predict who is most likely to respond to cancer immunotherapy?
Mobbed posters indicate attendee interest, but is it justified?
A look at Apexigen's anti-CD40 data in advanced pancreatic cancer - hit or miss?
What are the emerging trends from AACR19? What can we expect to see emerge over the next year?
Preview of AACR19 in Atlanta and what you need to know about ten novel cancer targets with data at the meeting.
In the second part of our review of the AACR19 cancer immunotherapy program, we take a look at more noteworthy sessions in Atlanta.
First part of a look at the immune-oncology track at AACR19 - there's a LOT going on this year!
Do we need to target Tregs in order to get more anti-cancer efficacy with immunotherapy? We take a look at what we've learnt about this niche.
In order to generate more IO therapies, we first need to get a better grip on the underlying biology.
Update on T cell bispecifics and other key topics in early stage IO development
A snapshot of 3 UK cell therapy companies, Autolus, Achilles and GammaDelta Therapeutics
Figuring out how to combine different IO approaches will take time so what have we learned lately?
PARP plus IO and IO combos are becoming all the rage, what can we learn from early signals?
TC BioPharm are a cell therapy company to watch out for as they look towards an IPO in 2020
What can we learn about gamma delta T cell cancer immunotherapy in China?
A look at the γδ T cell competitive landscape with cell therapies, antibodies and bispecifics in early stage development
Can we make novel allogeneic cell therapies with γδ T cells? We find out!
Can γδ T cells be employed as a therapeutic against cancer?
Targeting STING in cancer with a systemic small molecule approach? What's the story?
What does a next generation STING agonist look like and what issues is it attempting to address?
An in-depth look at the growing STING R&D landscape in oncology
What's hot in renal cancers? We take a look at what to expect at ASCO GU19 and offer insights on the emerging data
What can we learn from the key trials being presented at ASCO GU19 in San Francisco?
A review of key abstracts in prostate cancer expected at ASCO GU19 in San Francisco
We take a look at several key developments in myeloma on the antibody and cell therapy front.
What's new about p53 mutants and MDM2 inhibitors?
Should you read a book on the History of Cancer Immunotherapy? Here's our review...
Analysis and predictions of two oncology phase 3 readouts coming soon...
New insights emerging from research on cytokines as an effective way to induce anti tumour immunity
An upcoming small biotech focused on IO targets with their novel platform approach
Some examples of potentially useful biomarker inclusion in early oncology trials
What to watch out for at the ASCO GI19 conference in San Francisco
Going beyond anti-PD1 checkpoint blockade is important if we want to help more people respond to cancer immunotherapy
Drugging the undruggable with creative approaches to molecule development
Commentary on some up and coming biotechs in the oncology space
Insights and commentary from the second day at #JPM19
Insights and commentary from the first day of JPM19
Beyond T and NK cells, other immune cells can be used for cell therapies in solid tumours
FDA slaps a partial clinical hold for unwanted side effects, now what?
A rock around the breast cancer clock with cancer immunotherapies and targeted agents from SABCS18
How do we improve CAR-T cell therapy in CLL? A look at clinical data plus a new thought leader interview in the space.
Review of a round dozen key abstracts at #ASH18, both scientific and clinical data is under the microscope!
We offer 13 key highlights from day 2 of ASH18, including some surprises.
Highlights from Day 1 of the 2018 ASH conference held in San Diego
Highlights from the AACR special conference on tumour immunology and immunotherapy
From one BCMA directed CAR in 2015, we now have a very competitive niche in multiple myeloma. What's in store?
What to watch out for in the ASH18 LBA session
There are a number of important lessons we can learn from early phase 1 trials. Here are some of them.
AstraZeneca miss on OS in the phase 3 MYSTIC trial – what next? At one point we were posting…
What is old is new again - a look at some forgotten oncology targets that are coming back in fashion
Update on PIVOT-02 with nivolumab plus NKTR-214 in 1L metastatic melanoma
The evolving story of how commensal microbiota can affect response to cancer immunotherapy
Latest news and insights on immune escape mechanisms associated with cancer immunotherapy
Can we improve on the tolerability of the nivolumab-ipilimumab regimen by designing better a checkpoint inhibitor?
An extensive round-up of what to expect from SITC18 ahead of the abstract reveal
A top-line review of the ASH18 abstract palooza
Achilles Therapeutics is an emerging biotech in the cell therapy space that is based on truncal neoantigens
Initial results from the neon NEO-PV-01 phase 1B trial presented by Dr Patrick Ott
With new data on the blood-based TMB test at ESMO, what can we learn about this approach?
A discussion about the impact of the olaparib on the PARPi niche based on the findings of the SOLO1 trial
New trends in early drug develoment and Developmental Therapeutics
Wins for Pharma, some shakeouts for small biotechs on manic Monday at #ESMO18
Highlights and lowlights from Munich
Highlights and lowlights from Day 2 of #ESMO18
Highlights from Day 1 of #ESMO18 in Munich
Can we use technology to squeeze more out of B cells to generate an army of killer T cells?
The changing face of renal cell cancer from several perspectives
A look at the CheckMate-331 and CheckMate-451 study and other SCLC trials
A dozen poster abstracts to watch out for at ESMO18 on a wide range of topics...
Third ESMO18 preview on oral abstract presentations
A look a progress on NeoVax in GBM, RNA vaccines and even a novel CAR T cell therapy with a difference.
Some key notes on CAR T cell therapy developments ahead of SITC18 and ASH18
Highlights from the first day of #CICON18 in New York
ESMO18 Preview 1 - Late Breaking Abstracts to watch out for
After the WCLC2018 preview, what does the data actually teach us? A round up and commentary on 16 key trials
Our second preview of what to expect at CICON18 - top 10 poster abstracts
Part 1 of our #CICON18 Previews - a look at 11 intriguing IO related studies
Cell therapy is a very broad church - here's an interesting approach to keep an eye on
A fresh look at a class of targeted therapy agents that are beginning to look promising in some cancer patients
Update on BCMA, SLAMF7 and other targets in multiple myeloma
What to watch out for at WCLC2018 in Toronto later this month
Four areas of research in oncology R&D that may involve new targets or new indications emerging
Will NK cell engagers have a positive impact on checkpoint therapy and other adaptive immunotherapies?
Lessons learned from recent failure and a look at where a few new developments might be coming from...
On launched products, armored CARs and the potential threat from China
On targeting immunosuppression and some obscure oncogenic targets
Are the PARPi a class effect or are there real differences between them that may become more apparent in future combo studies?
Five key recent papers that are well worth looking at and what the science teaches us about next directions
Beyond PD-1 and CTLA4 there are other checkpoint and IO targets being investigated. We take a look at one of the promising ones...
An in-depth look at Adaptimmune's TCR T cell therapy program
Rumination, notes and updates on CAR-T cell therapy, checkpoint blockade, SCLC, genomics and TCR signalling...
One of the ongoing challenges with cancer immunotherapy is monitoring response to treatment. Even if you…
Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.
The latest part in our cytokine mini-series explores the potential for incorporating them in CARs or combining with checkpoint blockade through the lens of an expert in the field...
Where are Blueprint going with their various programs involving targeted therapies in a range of different cancers?
What can we learn from the updated Nektar NKTR-214 data presented at #ASCO18?
Update on TLR9 as a target and what we learn from the latest clinical data
Thoughts, reflections and learnings from the recent phase 3 lung cancer readouts from a lung cancer specialist...
Highlights and Lowlights amongst targeted therapy data at ASCO 2018
Ongoing discussion and debate about data in lung cancer and up and coming innate immunotherapies that may move the needle in IO-IO combos.
Dr Gilberto Lopes discusses the KEYNOTE 042 and 189 trials in first-line non-small cell lung cancer (NSCLC).
The promise and pitfalls of Day 1 of #ASCO18
We explore the importance of looking under the hood at various expression levels...
Not all IO-IO combos will be successful in solid tumours, what can we learn from the Genmab-Janssen news for daratumumab in NSCLC?
It’s a Bank Holiday weekend on both sides of the pond, which is always a good excuse for some…
Can TMB replace PD-L1 as a predictive biomarker of response for immune checkpoint blockade therapy?
A preview of key abstracts in urothelial and bladder cancer expected to be presented at ASCO18
What do we learn from the ASCO abstract release? Quite a lot! Here we debunk some of the controversial issues and inaccuracies that have arisen
Key themes and topics of interest in the poster halls - what stands out amongst several thousand posters?
What to watch out for at ASCO18 in the oral presentation sessions
A look at the history of CAR T cell therapy design and where things are headed in the future with one of the original cell therapy pioneers
A look at path to market strategies open to a small biotech in the CAR-T cell space
How do we drive more T cells into the tumour? Here's one company who are looking to do just that.
Going beyond PD-1, PD-L1 and CTLA-4 to explore other inhibitory checkpoint targets that may be useful in the clinic
A look at various lessons from recent IO trials and how they can applied to new readouts expected at ASCO18
A look at how basic and translational evidence points towards TGFβ as a possible new target for IO combos in some tumour types
A look at one way with which we can target the tumour microenviroment to improve response of cancer immunotherapy
What can we learn from the TRACERx studies in lung and renal cancers? Quite a lot, it seems...
4 KOLs tell us what they really thought about the 3 studies in 1L NSCLC presented at AACR18
A look at TMB as an emerging biomarker for cancer immunotherapy - is it ready for prime time?
Answering questions on the 1L NSCLC data presented at #AACR18
A look at the latest 1L NSCLC trial readouts
A look at the Class of 2018 new products in development - a hit or miss?
A look at some new - and very early - directions in CAR T cell therapies, especially in solid tumours.
How can we improve on monotherapy with PARP inhibitors? How do we address primary and acquired resistance?
Will the results from Merck's KEYNOTE-042 study change practice in 1L NSCLC?
Beyond the news that Incyte and Merck's epacadostat plus pembrolizumab combo failed to hit its endpoints in advanced melanoma, what other IO-IO combos should we turn to?
A look at an emerging IO target that might be useful in ceratin tumour types and patient subsets when given in combination
What's hot at #AACR18 in terms of data to watch out for in a certain tumour type?
A look at the clinical features that predict for early discontinuation with checkpoint blockade in ovarian cancer
An in-depth look at the French biotech company Innate Pharma and where they are now two years on from our last look at their IO pipeline.
What can we learn from the early data exploring PARPi plus checkpoint blockade combinations in ovarian cancer?
A post mortem of the Rova-T TRINITY trial and a look to the future in SCLC
A look at the key lung cancer data expected at AACR18 and what to expect from the latest squamous NSCLC
A look at what Gamida Cell, an up and coming cellular and innate immunotherapy company are up to...
A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies
A look at the history of NK cell development and where we're going in future with this IO approach
Our latest primer explores NK cells and their role in oncology R&D - it's an up and coming area
Some key highlights from the recent inaugural pancreatic cancer symposium in Houston
A look at an emerging area for biomarkers and stealth cancer therapeutics
A look at some of the issues underlying IO-IO combos and whether they can help us assess if these trials will succeed - or not.
In this post, we take a look at new clinical and scientific findings that may pave the way forward for the future in the CAR T cell space
What did Dr Grupp and Dr Komanduri learn from participation in the CAR T cell therapy trials?
A look at innate approaches to stimulating the immune system including IL-15 agonists
Insights from researchers in the CD47 niche - what do they really think?
A look at the players in controversial CD47-SIRPα landscape
A look at the changing face of the RCC landscape, including current and near term trial readouts
As inconsistent data abounds, is it time to move on from PD-L1 as a biomarker of response to checkpoint blockade?
A look at some new targeted and IO combinations in development for advanced prostate cancer
Will apalutamide and enzalutamide make headway in the M0 prostate cancer setting?
A look at biology behind targeting CD47 in cancer and some of the controversies plaguing the space
Highlights and Lowlights from ASCO GU 2018 - what to watch out for.
Interview with Dr Daniel George on Phase 3 PROSPER trial results
BMS announced that CM-227 hit PFS in lung cancer patients with high tumour mutation load, now what?
A look at Dr Malcolm Brenner's work on virus specific T cell therapies
FDA places Bellicum's BPX-501 on clinical hold - what's the story and what's next?
At ASCO-SITC this weekend there was some compelling new scientific data highlighting subsets of patients who might be eligible for cancer immunotherapy, including novel combination approaches.
Expert interview with Dr Glen Barber reignites the controversy over whether STING agonists could cause metastasis in cancer patients.
A look at where we are in pancreatic cancer and how the landscape has evolved of late...
A look at the pipeline of the up and coming Seattle biotech, Alpine Immune Sciences
Can STING agonists promote cancer metastasis in some patients? That's one of the key questions from new research linking chromosomal instability with tumor metastasis through activation of the cGAS-STING pathway.
PharmaMar's lurbinectedin misses in phase 3 platinum resistant ovarian cancer
A look at 8 key abstracts being presented at #GI18 in San Francisco this week.
How does positive trials from Roche and Merck impact the 1L NSCLC landscape?
A look at how new approaches in synthetic biology could revolutionise cell therapy in solid tumours
Commentary on Day 3 at 2018 JP Morgan Healthcare Conference in San Francisco
Interview with Syros Pharma CEO Dr Nancy Simonian
Commentary on Day 2 of the 2018 JP Morgan Healthcare Conference in San Francisco
Commentary on Day 1 of the 2018 JP Morgan Healthcare Conference in San Francisco
New series on Key Trends in Oncology for 2018
New approaches that enter a market unexpectedly can disrupt the status quo and push out more severe therapies to later lines of treatment
A look at key pipeline developments in multiple myeloma through the lens of a global expert in the field
Where is the venetoclax BCL-2 program going in hematologic malignancies?
An interview with Dr John Leonard exploring his thoughts on some of the key lymphoma data at #ASH17
As we see new readouts emerge with different doublets and triplets in CLL, how will they impact the treatment landscape?
Commentary on Sunday at 2017 ASH annual meeting in Atlanta
A look at some of the sessions and learnings from the first day at ASH 2017
People love hearing about new or emerging cancer targets - there's always the hope that one might find something cool that could move the needle and really make a difference...
The first phase 3 trial in 1L NSCLC to hit the PFS endpoint is Genentech's IMpower150. What can we learn from this study?
A look at the latest CDK4/6 inhibitor data including the important phase 3 trial with ribociclib (MONALEESA-7).
A look at what's hot in CAR T cell therapies at #ASH17
The Mav's key oral abstracts to follow at #ASH17 -- warning this list includes quirky selections!
A look at a selection of promising Developmental Therapeutics abstracts from ASH17 - what's in store this year?
A look at loss of heterozygosity and what it means for new lung cancer therapies
Integrated biomarker approaches are beginning to emerge to help researchers segment patients better for appropriate therapy. Here's one approach...
A look at the cabiralizumab plus nivolumab combination in PDAC at SITC over the weekend
A look st Syndax's entinostat and what happens when given in combination with pembrolizumab in melanoma and lung cancer
A look at Nektar's promising IO portfolio and what's next for the up and coming biotech
Ten stars from the clinical presentations on Day 2 of SITC 2017
A CAR T cell therapist's perspective on the Juno JCAR015 ROCKET dataset
A look at some of the main events from the first day at SITC 2017 - including Juno's ROCKET data.
Final SITC17 Preview and a look at key talks now that the abstracts are available.
A look at new targets, molecules and approaches to cancer research from #TARGETS17 in Philly
Science Fridays: A look at six key studies recently published on cancer research that BSB readers can learn from.
A look at up and coming emerging therapies in the DLBCL space
Highlights from Day 3 of the AACR-NCI-EORTC Molecular Targets meeting in Philadelphia
Commentary on Day 1 of 2017 AACR NCI EORTC Molecular Targets and Cancer Therapeutics Conference in Philadelphia
A look at ROVA-T's chances in the upcoming phase 2 TRINITY trial readout
A look at the SCLC landscape including some promising new developments
A look at the trials and tribulations for Immune Design's CMB305 and what's the latest in 1L NSCLC
What other approaches might be useful for predicting response (or non-response) to cancer immunotherapies?
With increasing evidence that CD123 is a suboptimal target in AML, what other approaches might be more useful to consider?
A look at some of the LBA posters to be presented at #SITC17 in November
A look at 5 key oral late breakers at #SITC17 and what to expect or watch out for
Can we address inhibitory factors that dampen NK cells to enhance the anti-cancer effect on tumours?
Our latest predictions in 1L NSCLC and what to expect from the upcoming trial readouts in this niche
A look at what's different about exceptional responders in PDAC and what can we learn about neoantigen approaches here?
A look at the latest developments in cancer immunotherapy in ovarian cancer, with a particular focus on neoepitopes and cancer vaccines.
Interview with Prof Kees Melief, CSO ISA Immune System Activation Pharmaceuticals
A look at Ugur Sahin's BioNTech and personalized mRNA vaccines
Genentech have several cancer vaccine collaborations in place, where do they see the future going in this niche?
Part 1 of a new mini-series on cancer vaccines. This one covers an update on Neon's neoantigen approach...
After pseudoprogression, the IO field has moved onto hyperprogression. What is it and why does it matter?
Is the CAR T cell therapy space ready for disruption? At least one researcher thinks so. What does this entail?
A post mortem analysis of the Bavarian Nordic PROSTVAC cancer vaccine trial failure in CRPC
An early look at a new IO combination that may help overcome resistance to checkpoint therapy
A look at the last day of ESMO17 with key data on cancer vaccines, checkpoint and targeted therapies to explore
A roundup of the key trials and targets presented on Sunday at #ESMO17
A look at mostly lung cancer highlights from the first 2 days at #ESMO17
Rucaparib likely joins the early maintenance PARP club in ovarian cancer with their ARIEL3 data at #ESMO17
A look at some of the small biotechs and what they're developing on IO front that looks intriguing at #ESMO17
8 key ImmunoOnc studies being presented at #ESMO17 this month
A look at what's happening with Cellectis and their clinical trial program with CD19 and CD123 CARs.
What does the future hold for Cellectis and allogeneic "off the shelf" CAR T cell therapy?
Gene editing looks set to become entrenched in allogeneic CAR T cell development, so what's new?
Does timing and sequencing of immune agonists impact their effect when given with checkpoint blockade?
A look at the changing HCC market and how pipeline agents may (or may not) impact the landscape...
After recent readouts of breast cancer trials at #ASCO17, where do we go next for future combos? Based on recent preclinical research, we have some ideas...
An eclectic selection of important abstracts involving targeted therapies to watch out for at #ESMO17
A look at the interim results from the BMS CheckMate-214 trial in renal cell carcinoma
Top 5 IO oral abstracts to watch out for in Madrid
A look at various factors that can influence cancer immunotherapy trials through the lens of an immunologist
A look at the role of pre-existing immunity in cancer immunotherapy trial readouts at ASCO17
Jumpstarting the immune system with a synthetic immunity approach - how can we do this?
How can we boost the efficacy of checkpoint therapies? One way is to drive more activated T cells into the tumour.
A look at AZN's miss with their IO-IO combination in 1L NSCLC
A look at why checkpoint therapy trials might be giving us inconsistent results of late
Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline
How we could use our immune system against Alzheimer's?
A look at the intersection of epigenetics and cancer immunotherapy - what can we learn and where are we going in this niche?
A second look at the evolving 1L NSCLC landscape with a focus on MYSTIC and IMpower150
Commentary on 2017 Paris Immuno-Oncology summit organised by European Academy of Tumor Immunology and Miltenyi Biotec
July Journal Club explores some intriguing new data around a cancer immunotherapy theme
A look at an up and coming small cap biotech developing targeted and immunotherapy agents for the treatment of cancer.
Notes on HGSOC, melanoma resistance and the evolution of NSCLC...
Coverage of European Association for Cancer Research EACR cancer genomics conference at Churchill College, Cambridge
Why did the IMvigor211 phase 3 trial with atezolizumab in UBC fail? BSB spoke to Prof Tom Powles.
Commentary from Day 1-2 of the 3rd EACR meeting on Cancer Genomics
A look at how liver mets can negatively impact cancer immunotherapies
What can we learn from the Immune Design data in sarcomas with their NY-ESO-1 vaccine?
What's new in the sarcoma space? Which novel approaches are worth watching out for?
Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...
Thought leader reactions and sentiments to the APHINITY readout in adjuvant HER2+ breast cancer
A look at checkpoint blockade in early stage breast cancer - encouraging or not?
A look at PARP as it journeys from 1999 to 2017 culminating in a plenary presentation at ASCO
Olaparib is the first PARP to demonstrate a clinical benefit in HER2- breast cancer - what do KOLs really think?
A look at the initial results from the Novartis CTL019 pivotal trial in aggressive lymphoma (JULIET).
Beyond the incremental improvements seen in clinical trials, what are the new trends emerging from ASCO 2017 that will impact oncology R&D?
Right now many people are overwhelmed not just with the sheer number of ASCO abstracts to process and…
Our Top 10 #ASCO17 abstracts to watch out for
Some intriguing surprises in the CAR T cell therapy abstracts this year...
A look at the FDA briefing docs on Puma's neratinib
A look at an up and coming niche in cancer research that may turn out to be useful in conjunction with checkpoint blockade
A look at 5 key abstracts that tickled my fancy from #ASCO17; Warning - not all are positive!
Update on #ASCO17 data for IDO1 inhibitors in various cancers
A fireside chat with a leading KOL involved in cancer research on resistance.
Durvalumab grabs pole position in unresectable NSCLC amongst IO compounds
We've been overdue a correction in the irrational exuberance around IO... is this the tip of the iceberg?
A look a one company's approach to DDR and potential combination opportunities in this niche
A look at a promising biotech in the neoantigen space - what's their approach and how might it fare?
With 'liquid biopsies' on the rise, we take a look at another potential candidate that could be useful - exploring exosomes.
A candid look at new approaches being explored in cold tumours using prostate cancer as an example
BSB Reader Mailbag on TRK/ROS1/ALK inhibitors
An interview with Dr Jonathan Lim, Ignyta on TRK/ROS/ALK inhibition
Through the keyhole with a look at AZN and MedImmune's IO portfolio
Expert interview at AACR17 with Dr Julie Brahmer on lung cancer immunotherapy resistance and preview of ASCO17 abstracts
Encouraging new developments in GBM with a novel CAR T cell therapy
How do we overcome resistance to cancer immunotherapies? Here, we have an in-depth interview with a thought leader in this space.
Dr Daniel Chen from Roche/Genentech shares his vision for the future of cancer immunotherapy at AACR17.
Five emerging cancer research trends we picked up at AACR17 that you should be aware of.
Interview with Professor Peter Schmid, Barts Cancer Institute.
Commentary on Tuesday at 2017 AACR annual meeting in Washington DC.
Commentary on Monday at the 2017 AACR annual meeting.
Commentary on Sunday at the 2017 AACR annual meeting
Highlights from Day 1 at AACR17
A look at some of the key sessions featuring checkpoint blockade at the AACR 2017 annual meeting
The third PARP inhibitor in ovarian cancer hits the market - what's the latest story?
A comprehensive review of the key abstracts in the CAR T cell therapy niche and hints of the latest emerging trends
A look at how research into transcription factors, super enhancers, chromatin regulation and broom/chromodomains is changing the way we look at cancer
With increasing competition in the CDK4/6 space in HR+ HER2- metastatic breast cancer, how are things shaping up?
Latest BSB reader Q&A looks at 5 questions from subscribers
A look at a new area of immune-oncology that looks set to be in the consciousness more over the next few years
PARP! PARP! What's hot in ovarian cancer at SGO and AACR?
Overcoming immune suppression in the tumour microenvironment
After exploring a mechanistic approach and a tumour type as part of our AACR annual meeting coverage, in…
A look at some recent clinical data and what we can learn from the new data expected at AACR in DC
The first of our strategic and thematic AACR Previews for the 2017 annual meeting is here
6 key trends and highlights of note from the inaugural ASCO-SITC meeting in Orlando, Florida
After a rocky 2016, what does 2017 hold for Juno as they switch focus from JCAR015 to JCAR017?
A look at another surprising factor that might affect efficacy of cancer immunotherapy and checkpoint blockade.
After JAK1/2 upregulation and PTEN loss, a third mechanism of resistance to checkpoint blockade has been identified. We discuss the issues around this latest challenge...
Insight from BMT Tandem 2017 meeting into latest Cell Therapy data
A look at cancer immunity and the new framework for exploring the cancer-immune setpoint.
A look at another approach for turning cold into hot (or warmer) tumours with cancer vaccines.
Targeted therapies aren't dead yet - oncogenic drivers are still important in many cancers. Here we look at progress in GIST, systemic mastocytosis and HCC...
A look at the deeper side of research - how the spliceosome and RNA splicing may be useful in cancer research.
Reader Q&A on women's cancers relating to HER2, PARP and TNBC...
A look at what we can learn from some recently published new papers in the oncology space.
Going beyond proteasome inhibitors and IMiDs in multiple myeloma - what novel targets are attractive?
What we learnt at ASH16 on how to better target the tumour microenvironment in lymphoid malignancies.
Exploring clinical trials with targeted therapies, including PARP and ATR inhibitors and combination approaches
A draft manifesto for IO in cancer research and what we need to learn
2017 could well turn out to be a good year for HER2+ breast cancer with several new developments ongoing. We take a look...
A look at gems from the #GI17 poster halls or molecules destined for Dog Drug Heaven?
A couple of trials at ASCO #GI17 look promising in terms of trial design with encouraging implications for the future in metastatic colorectal cancer.
Will gastric cancer be one of the next indications for nivolumab?
How crowdsourcing data from breast cancer patients may help future clinical R&D
Will cancer stem cell therapeutics impact the lives of people with metastatic breast cancer?
A look at the how several major phase 3 trial readouts will affect the 1L NSCLC landscape
SABCS16 expert interview on Inflammatory Breast Cancer with Dr Naoto Ueno from MD Anderson Cancer Center.
SABCS16 expert interview on the potential of circulating tumor DNA to change the treatment of cancer.
Update on Neon Tx as they move into commercial new product development with their neoantigen platform.
Second in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium features Dr Leisha Emens
First in a mini-series of expert interviews from the 2016 San Antonio Breast Symposium #SABCS16 with a leading researcher who has discovered a first-in-class compound with potential in metastatic breast cancer.
Commentary on Wednesday at JPM17 in San Francisco
Commentary on Day 2 of the 2017 JP Morgan Healthcare Conference in San Francisco
Commentary around some of the corporate presentations at Day 1 of the 2017 JP Morgan Healthcare conference in San Francisco.
Interview with Dr Stephan Grupp on the data he presented at ASH16 and what the future may hold for CAR T cell therapy in pediatric ALL
A look at some promising agents in new product development emerging in early CLL trials
How are recently approved novel therapies impacting the CLL landscape and where are we going next?
A look at the latest data for a CD79b targeted ADC in lymphomas
A look at the emerging trends we can expect in 2017 for cancer research
An in-depth look at the sudden and unexpected announcement underlying the clinical hold for Seattle Genetics anti-CD33 ADC Vadastuximab Talirine in AML.
Tackling heterogeneity in older people with AML using novel targeted therapies.
#LeonardList showcases 10 Lymphoma Abstracts at ASH16
We answer more questions on CAR T cell therapies and ADCs in acute leukemias from ASH
3 trends from SABCS16 that you may hear more about
A look at the new various developments in CAR Therapies targeting BCMA in multiple myeloma
We answer several critical questions that readers have sent in based on the CAR T cell data at ASH this week.
Highlights (Part 1) from 2016 ASH Annual Meeting in San Diego - 7 initial impressions
Gems from the Poster Hall on Wednesday at EORTC-NCI-AACR Molecular Targets meeting in Munich
Can we revert the mutant phenotype in breast cancer and return to a normal, non cancerous phenotype?
Highlights from the Charles River Immunotherapy Symposium in Munich, 2016
If you have plans to be in San Diego for #ASH16 what should you attend on Friday?
A most unfortunate follow-up to the ongoing safety issues with Juno's JCAR015 and neurotoxicity in the run-up to #ASH16
Without effector T cells in the tumour, checkpoints won't work. So how do we attract more in? Here's one way to do it...
A look at new ways to boost checkpoint therapy performance including agents in development from small biotechs
Update on important new data in urothelial cancers and how the landscape is moving quickly
Does adding lirilumab to nivolumab move the needle in relapsed SCCHN?
An in-depth review of what to expect from AML new product development in San Diego
What To Watch Out For in CAR T Cell Therapies at ASH in San Diego in December 2016
Initial impressions of abstracts for ASH16 in San Diego
Four more combination trials of interest in cancer research that may be worth watching out for
Four pretty cool approaches to combination cancer immunotherapy stood out at #ESMO16 in Copenhagen...
How will glycomics impact cancer research? Some interesting new developments are emerging in this field
Can biomarkers help us improve clinical trial outcomes?
How does the rucaparib data at ESMO fit in the treatment paradigm and what's next for PARPi?
Following the dispute between Tesaro and Myriad on HRD testing, here's Myriad's perspective on the data presented
Yesterday saw the FDA approval of atezolizumab (Tecentriq) for the second-line treatment of metastatic…
Commentary on Sunday at ESMO16 with a focus on the lung cancer data in the Presidential Symposium
Commentary on Day 2 at ESMO16
What you need to know about the Tesaro niraparib ovarian cancer data presented at ESMO 2016.
Commentary on Day 1 at ESMO 2016 Congress in Copenhagen.
Audio Slideshow tour of HalioDx lab that shows how digital pathology is used to calculate Immunoscore an immune based colon cancer assay
Latest BSB mailbag covers targeted therapies, immunotherapy and #ESMO16
Corvus Pharmaceuticals accelerates development of A2A receptor antagonist CPI-444 that could improve checkpoint responses.
Interview with Dr Eric Pamer on impact of the microbiota on the innate and adaptive immune systems and future directions.
New research shows potential of cell therapy with allogeneic memory-like natural killer NK cells in AML.
Interview with Prof Ton Schumacher at scientific meeting to celebrate 40 years of Centre d’Immunologie de Marseille-Luminy (CIML).
Interview with Professor François Romagné, Scientific Director of MI-mAbs, an immuno-oncology drug discovery venture in the Marseille Immunopôle cluster.
Interview with Innate Pharma CEO Dr Hervé Brailly on clinical trial readouts expected and his vision for company
Professor Eric Vivier is Director of the Centre d’Immunologie de Marseille-Luminy and a co-founder of Innate Pharma and the Marseille Immunopôle. He is a leading researcher in the field of innate immunity.
Interview with HalioDx CEO Vincent Fert on commercial strategy for Immunoscore diagnostic test.
A look at some of the key breast cancer abstracts to watch out for at #ESMO16 in Copenhagen
Five key approaches in developmental therapeutics in the spotlight at ESMO16
A look at 9 key abstracts in ovarian cancer at #ESMO16 and what to expect
What can we expect in Head & Neck cancer at #ESMO16 in Copenhagen?
A look at what to expect from the lung cancer late breakers at #ESMO16 - are there any surprises or controversies?
Overcoming barriers to resistance in epithelial cancers - a look at a novel oncogenic target
Launch of the BSB Journal Club - this inaugural edition explores T cell dysfunction and exhaustion
Interview with Prof Fran Balkwill from Barts Cancer Institute on 3D modelling of the tumor microenvironment in ovarian cancer
Part 2 of interview with PsiOxus Therapeutics CEO Dr John Beadle discusses corporate strategy and challenges faced by an emerging biotech company.
An innovative and promising approach to cancer immunotherapy using adenoviruses to deliver multiple warheads to tumours
A primer on the oncolytics viral therapy landscape - beyond T-VEC
This is the second in our mini-series on neoantigens and looks at whether neoantigen based cancer vaccines can make a difference in the treatment of solid tumors.
Cary Pfeffer of Third Rock Ventures describes how a novel neoantigen vaccine in academia transitioned into a commercial company with exciting prospects...
A primer on neoantigens and their importance in cancer research
The BMS CheckMate-026 trial in 1L NSCLC did not meet it's primary endpoint. What can we learn from the failure?
Collaborations in the adoptive cell therapy space have now branched out from autologous to allogeneic products. What's the skinny?
What factors contribute to resistance with checkpoint blockade and how can this be overcome?
July Reader Q&A - thoughts on Jounce, Celgene, BMS, J&J and CAR T cell therapies...
Lilly and Boehringer Ingelheim have announced a clinical trial collaboration in metastatic breast cancer with the CDK4/6 inhibitor, abemaciclib, and the IGF antibody, BI 836845.
A example of how different targeted therapy and immunotherapy combinations could be both useful and different from what we've seen before
Juno ROCKET trial put on clinical hold following 3 death due to cerebral edema. What's the skinny?
Will priming the tumour microenvironment with epigenetic therapies such as HDACs lead to enhanced activity with subsequent immunotherapy?
With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.
How will niraparib impact the ovarian cancer market?
The oncology bispecific market is heating up with J&J collaborating with Macrogenics and Novartis with Xencor. We discuss the skinny...
We've seen some wonderful responses with checkpoint blockade and cancer immunotherapies, but there are some downsides that need to be considered.
Can we turn a cold tumour into a hot one where some patients can respond to therapy?
Update on ASCO checkpoint blockade data for colorectal and other MSI-High cancers
An easy to use new biomarker emerges to help oncologists select colon cancer patients for cancer immunotherapies.
Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?
Can we find and use several biomarkers to triangulate responders and non-responders?
A look at the increasingly competitive metastatic urothelial carcinoma landscape
What to make of the various combination trials presented at ASCO 2016?
A number of points of strategic importance fell out of the ASCO data dump. What are they and why do they matter?
Commentary from Monday at ASCO 2016 American Society of Clinical Oncology annual meeting in Chicago
Prior to chemotherapy men with advanced prostate cancer did not live longer if they received ipilimumab compared to just receiving placebo. The phase 3 trial was a failure.
Top-line commentary from Sunday at ASCO 2016 annual meeting.
Top-line commentary from Saturday at ASCO 2016 annual meeting.
What are our Top Ten immunotherapy abstracts of note at ASCO 2016?
The poster childs for targeted therapies have been surprising - CML and lung cancer -- what's new here at #ASCO16?
The bromodomain market has exploded in recent years with many more agents in the development. Are they all the same though?
Can we safely combine a STING agonist with a checkpoint inhibitor to generate more effectiveness in melanoma and lymphomas? We asked experts at AACR what they really thought...
A look at Bayer's early oncology pipeline and a curious new class called MNK (Mink) inhibitors
What can we learn about clinical trial design from immunotherapy combinations?
Commentary from the AACR Precision Medicine Conference in Miami on Targeting the Vulnerabilities of Cancer.
How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!
A look at small biotechs producing quality preclinical data at #AACR16 that may lead to clinical development in the near future
A look at the BCMA/APRIL landscape in multiple myeloma - this is rapidly becoming a competitive target
Beyond checkpoint blockade, companies are now exploring what happens when you combine them with immune agonists such as OX40. Here we explore an industry perspective.
A wide ranging discussion about how to light the fires in non-immunogenic or cold tumours - OX40, STING, vaccines and more discussed!
Can we safely and effectively add a checkpoint inhibitor to standard chemotherapy and VEGF inhibition? Early proof of concept in patients with metastatic colorectal cancer.
At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.
Chemotherapy can have a potentiating effect on cancer immunotherapy. The positive effects may surprise some readers...
What were the major learning points from AACR that will make an impact over the next 1-2 years? Chhhhanges are afoot...
Season 2 of the Novel Targets has launched, plus the eagerly awaited April Readers Q&A Mailbag
Can we use technological approaches from oncology to applying creative ways to treating bacterial infections?
Commentary on Tuesday sessions at AACR 2016 annual meeting
Commentary on Monday at AACR 2016 annual meeting
Commentary from Sunday at 2016 AACR annual meeting
Commentary on Day 1 of AACR 2016 annual meeting in New Orleans.
Where next for Bcl2 inhibitors beyond CLL and Del17p? Which novel combinations might be an attractive strategy?
First-line data for AstraZeneca’s ($AZN) third generation EGFR inhibitor osimertinib (Tagrisso) impresses at the 2016 European Lung Cancer Conference in Geneva.
In this preview of AACR 2016, we're looking at the CD40 landscape, some of the new companies that have entered the scene and what presentations to look out for at AACR 2016 (and why they matter).
Today post is on OX40 (CD134) as a novel immuno-target and what the OX40 cancer immunotherapy landscape looks like.
There are now several agonist antibodies in development and entering the clinic that seek to activate GITR, and new data is expected at AACR 2016.
This post looks at some of the data at AACR 2016 for cancer immunotherapies that target IDO1 and TDO and their downstream effectors.
The discovery of a novel target in castration-resistant prostate cancer offers the potential to overcome or delay acquired resistance to enzalutamide.
A look at alternative checkpoint inhibitors, anti-TIM-3 and LAG-3 compounds in early development at AACR
In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.
Commentary on some of the latest cancer immunotherapy papers
Subscriber questions on recent immuno-oncology, Genentech, Kite Pharma and Gilead company news
Pick of 10 abstracts at AACR 2016 annual meeting in New Orleans that may answer critical cancer research questions
Cancer Immunotherapy dominates AACR 2016 annual meeting in New Orleans.
Finding new ways to optimise CAR T cell therapy in CLL and solid tumours may be closer than you think...
Review of 4 noteworthy posters at the 2016 European Breast Cancer Conference in Amsterdam organised by European Cancer Organisation ECCO
Trends in Haplo stem cell transplants may impact Bellicum Pharmaceuticals adjunct T Cell therapy BPX–501
Could immune resistance be reversed or prevented by the addition of appropriate checkpoint blockade? Which ones matter though, that is the critical question?
Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy
Commentary on presentation by Dr Philippe Armand at BMT Tandem meeting on “Checkpoint Blockade in SCT, Data & Hope, Promise & Peril”
Interview with Dr Michael Jensen on CD19 CAR T Cell Therapy
Interview at BMT Tandem 2016 with Dr David Porter U Penn on CD19 targeted CAR T cell therapy in CLL
Preview of noteworthy sessions at 2016 BMT Tandem meeting in Honolulu, Hawaii
How do we decide how to incorporate the newly approved drugs in Multiple Myeloma and what's the next wave of therapies we can expect to see evolve?
What are some of the strategic trends and drivers in the Graft versus Host Disease (GvHD) space at #BMTTandem16?
Unum have developed a completely different approach to traditional CAR T cell therapies. Will they make an impact in patients?
A novel cell therapy approach uses T cells targeting multiple tumor-associated antigens.
Who will move the needle in gastric and oesophageal cancers - targeted therapies or checkpoint immunoherapies?
Will checkpoint blockade be effective in multiple GI cancers and if so, why?
A trial of gemcitabine plus cisplatin plus ipilimumab in patients with metastatic urothelial cancer failed to meet it's primary endpoint.
A novel non-invasive liquid biopsy may offer a potential novel biomarker that will help in sequencing prostate cancer drugs.
How do we overcome resistance to Zytiga? There are some encouraging developments in this area to report.
Two biotech companies are in a race to market for a novel target in advanced prostate cancer.
Commentary on Wednesday corporate presentations at 2016 JP Morgan Healthcare conference in San Francisco
Commentary on some of the presentations at Day 2 of JP Morgan Healthcare conference in San Francisco.
Commentary around some of the corporate presentations at Day 1 of the 2016 JP Morgan Healthcare conference in San Francisco.
An interview with Seattle Genetics CEO, Dr Clay Siegall on CD19A ocular toxicity and the competition from checkpoint inhibitors in Hodgkin's lymphoma.
An in-depth look at the FLT3 inhibitor midostaurin and its potential impact on the treatment for AML.
ASH 2015 interview with Dr Ian Flinn, Director of the Blood Cancer Research Program at the Sarah Cannon Research Institute.
A look at the new CLL 17p deletion data at ASH in the late breaker session
Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.
Part 1 of an interview with Prof Waseem Qasim.
Five promising new agents in development for the treatment of ER+ or HER2+ or triple negative breast cancer emerge from #SABCS15
Adding chemotherapy or an ADC boosts the immunogenic effects prior to checkpoint therapy in metastatic breast cancers
Commentary on "Manic Monday" at ASH 2015
Commentary on Plenary Sunday at the 2015 ASH annual meeting in Orlando.
Commentary on Saturday at ASH15
In the last of our American Society of Hematology (ASH) 2015 annual meeting previews, we take a broad…
There are an encouraging number of promising therapies in development for Aggressive Lymphomas at ASH this year - which ones should you watch out for?
With four new approvals in multiple myeloma in 2015, ASH is expected to have a surfeit of riches to review for this disease...
Where is the field of immune biomarkers going beyond PD-L1 in the next few years?
Checkpoints in classical Hodgkins Lymphoma - how is the data holding up one year on?
At the recent Society for Immunotherapy of Cancer (SITC) annual meeting, Dr Chris Heery presented a poster on the results of a phase 1 clinical trial to evaluate the safety and tolerability of a therapeutic vaccine targeting brachyury.
A look at the FLT3 AML landscape - what's new?
Our latest Q&A based on reader questions - In the Hot Spot: On CAR T cell therapies
Preview of some of the late-breaking abstracts at the 2015 annual meeting of the American Society of Hematology ASH15 in Orlando.
Interview with Dr Mario Sznol on Novel Immunotherapies and Combinations
Dr Tom Gajewski (University of Chicago) talks about work from his lab that shows the gut microbiota can impact the efficacy of checkpoint inhibitors.
AstraZeneca's AZD9291 was approved by the FDA in EGFR T90M mutation positive lung cancer today and is now known as osimertinib or Tagrisso.
Interview with a leading expert on strategies to overcome CAR T Cell Therapy Resistance
At SITC 2015, we heard a tremendous amount of data, but a fresh controversy emerged regarding checkpoint inhibition...
Expert opinion on First Clinical Application of TALEN Engineered Universal CAR19 T Cells in B-ALL
Enoblituzumab is an immune stimulant that targets B7-H3 leading to more T cells.
Is Incyte's epacadostat (IDO1 inhibitor) ready for prime time?
Review of the highlights from the SITC 2015 pre-meeting workshops
Most of the abstracts for the 2015 annual meeting of the American Society of Hematology (ASH) have just gone online. This is a quick initial preview of a few that caught my attention in the immunotherapy space.
Commentary on the International Cancer Immunotherapy Symposium held at SITC 2015
Preview of what's hot at the 2015 Society for Immunotherapy of Cancer (SITC) annual meeting at National Harbor, MD.
Companies in the ImmunoOncology space are looking at ways to improve responses with checkpoint inhibitors. Adding an immune agonist is one way to do this.
A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.
Interview with Dr Jérôme Galon on Immunosurveillance, Immunoscore and Personalized Cancer Immunotherapy.
Preview of the key topics coming up at the AACR-NCI-EORTC Molecular Targets meeting in Boston, including Pasi Janne's interesting data on T790M negative NSCLC...
Finding a biomarker for EGFR monoclonal antibodies in colon cancer has proven elusive but things may be a-changin'...
Radiation has the potential to generate an immune response that may lead to an abscopal effect when combined with a checkpoint inhibitor.
Some promising new clinical targets emerged at ECC in Vienna, including DLL3 in SCLC, TRK gene rearrangements, Notch3 and PTK7. What did we think of the data and what issues should you look out for?
Will an increase in ILD cases scupper the AZD9291 plus durvalumab combination study in lung cancer? Will there be an advantage for Clovis or not?
At the 2015 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting Barcelona on Friday, Dr Stephen Hauser (UCSF) presented the data for octrelizumab, an anti-CD20 monoclonal antibody, on behalf of the investigators in the OPERA trial.
Should we be using the PDL1 antibody assay to screen patients for therapy with anti-PD1 and PD-L1 checkpoint inhibitors or? How useful is the test? The debate is heating up!
Interview at ECC 2015 with Dr George Demetri on new developments in Soft Tissue Sarcoma
Interview with Dr Nora Disis about the phase 1b trial results for avelumab in ovarian cancer and the challenges of developing these agents in non-hypermutated tumour types
Commentary on Day 3 of the European Cancer Congress in Vienna
Commentary on Day 2 of the European Cancer Congress in Vienna
Highlights from Day 1 of the ECC 2015 (ECCO) meeting in Vienna
What happens when we literally step on the gas with immune agonists?
T cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) is widely expressed on immune cells. What's the potential for a TIM-3 checkpoint inhibitor?
Review of noteworthy abstracts at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York
Holbrook Kohrt is a Stanford medical oncologist and clinical researcher who is leading the way in cancer immunotherapy combination strategies targeting CD137 (4-1BB).
Immunocore is an immuno-oncology company with an innovative approach to targeting T Cell Receptors (TCR) using their proprietary ImmTAC (Immune mobilising monoclonal TCRs against cancer) technology platform.
What's hot at ECCO 2015 in the oral sessions? An in-depth preview of what we can expect to hear about in Vienna...
What's hot in the 2015 ECCO late breaking abstracts in Vienna? Find out here...
Atezolizumab is expected to change the standard of care for the treatment of metastatic urothelial bladder cancer
The role of basket trials in small cancer subsets will be important to defining what targeted therapies work well...
Dr Carl June on progress of CAR T cell therapies in CLL, myeloma and solid tumours
We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...
Oncolytic viruses are fast becoming a hot new area in cancer research but who are the players and where is this field going?
Exploring NY-ESO-1 as a valid target in sarcoma, multiple myeloma and metastatic melanoma...
Some interesting potential new therapeutic approaches on the horizon in pediatric ALL - beyond CAR T cell therapies lie Bcl2 inhibitors
Will checkpoint inhibitors make their mark in renal cell carcinoma and how will they be integrated into a treatment paradigm dominated by VEGF inhibitors?
This month's Biotech Strategy Blog mail bag.
Interview with Dr Rob Iannone of AstraZeneca on their IO pipeline
As we learn more about mechanisms of resistance in ALK+ and T790M mutated lung cancer, combination strategies are likely to evolve - but which ones?
Clovis have started their rolling NDA for rociletinib in T790M-positive lung cancer - what about AstraZeneca's AZD9291?
Interview with Dr William Pao on the Roche antibody based cancer immunotherapy strategy.
Editas presented some elegant work using their gene editing technology with CRISPR/Cas9 to modify T cells at ASGCT. Who would have guessed a short time afterwards Juno and Celgene would sign a 10 year collaboration?
ASCO 2015 interview with Dr James Gulley from NCI on Prostate Cancer Immunotherapy.
What's hot in soft tissue sarcomas at ASCO 2015? Find out more...
Insights on targeted therapies from ASCO - questions from subs on neratinib, bavituximab, enzalutamide, Gilead's pipeline and MDSCs...
We've heard a lot about checkpoint immunotherapies in non-small cell lung cancer (NSCLC), but what about it's deadlier cousin, small cell lung cancer (SCLC)? Find out more...
Beyond the Big Four in checkpoint inhibitors, there is a raft of other companies anxious to get in the action. We take a look at Merck Serono and their progress with avelumab, an anti-PDL1 antibody
How do we help patients who are non-responders or have stable disease respond to checkpoint inhibitors? Will chemotherapy combos help or not?
Highlights from Monday at the 2015 ASCO annual meeting in Chicago
What's hot on Plenary Sunday at ASCO 2015? We'll be updating this blog post during the day.
Highlights from Day 2 at ASCO 15 in Chicago
Reflections on data presented in the first cancer immunotherapy press briefing at ASCO 2015
Do you need to incorporate a suicide suicide switch into CAR T cells that allows you to turn off the response, force the T cells to self-destruct?
Targeting MYC and bromodomains is an emerging area of research as we learn more about super enhancer transcription factor clusters around oncogenes that drive cancer.
Data at ASGCT and ASCO highlight potential new treatments in development for multiple myeloma
At AUA 2015 in New Orleans, Dr Celestia Higano (Seattle) presented the results of the STRIVE clinical trial.
Update on checkpoint inhibitors in urothelial bladder cancer from AUA 2015 and what's in store for new developments with this disease.
First in a series of previews of ASCO 2015 annual meeting abstracts.
Dr Tom Gajewski is working on STING agonists that may have a major role to play in cancer immunotherapy.
At the 2015 annual meeting of the American Association of Immunologists (AAI) in New Orleans, leading experts shared their insights on the “Promise of Cancer Immunotherapy."
What are the hot checkpoint studies to watch out for at ASCO 2015? We created a cheat sheet to follow and track the data as tsunami hits...
What happens when we combine a checkpoint with an immune stimulant in advanced melanoma?
Beyond monotherapy with checkpoint inhibition, what combinations or sequences might be useful to explore next?
New developments in T790M and ALK lung cancer plus a look at antibodies targeting ADAM17 in head & neck cancer.
Beyond lung cancer and melanoma, what other tumour types represent the low hanging fruit for checkpoint monotherapy?
As the anti-PD-1 blockers show superiority in front-line metastatic melanoma, is this the end for Yervoy?
The annual meeting of the American Association for Cancer Research ended today. Find out what were our top 10 highlights.
Checkpoint Inhibitor data is a hot topic at AACR 2015. Data showed they may work in TNBC and also two checkpoints are better than one.
Cancer Immunotherapy is one of the hot topics at the 2015 AACR annual meeting in Philadelphia.
Updated data for the AURA phase 1 trial of AZD9291 was presented at the European Lung Cancer Conference in Geneva.
Does checkpoint blockade with CTLA4 have a role to play in hematologic malignancies?
University College London (UCL) is leading the way in European clinical trials of CAR T Cell therapies that target CD19.
Emerging data on different combinations with checkpoint inhibitors suggests that this may increase response rates and outcomes for cancer patients. Find out more...
Novartis have announced a deal with Aduro Biotech for access to their STING-targeted CDN platform technology.
The mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Novel targets are emerging in urothelial bladder cancer which may offer new therapeutic options for antibody and CAR-T cell therapy development.
Update in the PREVAIL trial in chemotherapy naive castrate resistant prostate cancer based on 765 deaths from the 2015 EAU conference in Madrid.
The results of the TERRAIN prostate cancer clinical trial data were presented at the 2015 European Association of Urology (EAU) Congress in Madrid today.
Why is renal cell carcinoma so challenging from a clinical and sequencing perspective?
What is the potential of a new cell therapy with cytotoxic T lymphocytes against Epstein Barr Virus (EBV-CTL)?
Predictive biomarkers of response will be key to reimbursement of immunotherapies in Europe. One is potentially emerging for ipilimumab (Yervoy), which may be useful in speeding up access.
What are the emerging new trends in cancer immunotherapy? Beyond monotherapy lies many combination opportunities yet to be explored. At AACR in April, we will see a raft of novel approaches being discussed.
Will checkpoint inhibitors make an impact in hematologic malignancies or will novel combinations be needed?
Not all cancers respond to checkpoint inhibitors - how can we change that situation? Here's one example, using prostate cancer as a model...
What's hot at ASCU GU 2015? Focus on prostate and bladder cancers with checkpoint inhibitors and sequencing therapies
Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.
The ongoing story of the AR-V7 splice variant as a potential biomarker of response in mCRPC
Which new combinations could improve outcomes for colon cancer patients receiving EGFR therapies by overcoming acquired resistance?
We've seen very little real progress in colorectal cancer beyond incremental improvements since Erbitux and Avastin were approved a decade ago. Are we on the threshold of a new paradigm shift?
Patients with BRAF driven colon cancer don't do as well as those with melanoma: how can we overcome acquired resistance to RAF treatment?
Cellular Biomedicine Group (NASDAQ: CBMG) has acquired rights to the Chimeric Antigen Receptor T cell (CAR-T) therapy of the PLA General Hospital in Beijing.
What does the evolving landscape for CAR, TIL and TCR cell therapies look like?
The NCI have been at the forefront of developing novel cancer immunotherapies for several decades, but what is the current status of their groundbreaking work? Find out more in this primer on TILs.
ABT-199 is now known as venetoclax - has it overcome it's checkered history to get back on track?
Clovis have observed responses in T790M positive AND negative lung cancer with rociletinib - implications for the commercial opportunity are discussed in this post.
The Phase 2 TERRAIN trial met its primary endpoint (PFS) with enzalutamide beating out bicalutamide in castrate resistant prostate cancer. What next?
Yumanity seeks to transform drug discovery for neurodegenerative diseases caused by protein misfolding.
If we truly want to see a more precision medicine approach evolve then we have to first find the oncogenic drivers. At ASCO GI one study in particular caught my eye and attention, but you won’t find it written up in the medical lay press and it’s not that obvious unless you know what you’re looking for.
Transcription factors are becoming a new buzzword in cancer research - why are they important for drug development?
Bluebird bio is an emerging biotech company with a novel lentiglobin gene therapy in development that could revolutionize the treatment of beta-thalassemia and sickle cell disease.
What's the vision for Bellicum Pharmaceuticals? In an in-depth interview CEO Tom Farrell and COO Annemarie Moseley discuss the benefits offered by their new products in development.
There is no available cure for patients with beta-thalassemia or sickle cell disease, but new developments are very encouraging
Biomarin have a good shot on goal with their PARP inhibitor talazoparib in gBRCA breast cancer
What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?
What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?
Graft versus Host disease (GvHD) is an area of tremendous unmet medical need that is triggering the interest of a number of biotech and rare disease companies.
In the last post of 2014, it’s time to address some pertinent questions on triple negative breast cancer (TNBC).
There is a lot of interest in checkpoint inhibitors, do they look they will be effective in Triple Negative Breast Cancer?
"Manic Monday" at the annual meeting of the American Society of Hematology features multiple oral sessions run at the same time!
Coverage of Day 2 of the annual meeting of the American Society of Hematology in San Francisco.
It's Day 1 of the 2014 annual meeting of the American Society of Hematology meeting in San Francisco.
There are a lot of new products in development for AML. Here's my top 10 abstracts to watch out for at ASH 2014 in San Francisco.
Preview of ASH 2014 Key Abstracts in Lymphomas including HL and aggressive DLBCL
ASH 2014 Multiple Myeloma data looks like it offers much promise for new treatments as well as an increasingly competitive marketplace
The science of targeting PD-1 and it's ligand PD-L1 in cancer immunotherapy is highlighted in five Letters published in Nature this week.
Ovarian cancer has lagged behind other solid tumours in terms of development, but this situation may soon change with promising new agents being developed
Clovis present their Phase 2 data with the new rociletinib formulation at EORTC-AACR-NCI in Barcelona
Agios AG-120 IDH1 Inhibitor shows promise in acute myeloid leukemia (AML) according to data to be presented at the EORTC-AACR-NCI Molecular Targets and Cancer Therapeutics Symposium in Barcelona
How can we jumpstart the immune system to enable more patients to respond? At SITC we learned more about targeting CD40 to achieve this.
At the SITC 2014 annual meeting, Dr van den Brink presented data on how the bacteria in our gut (the intestinal microbiome) can impact GvHD.
At the Society for Immunotherapy of Cancer (SITC) meeting last week, one of the Hot Topic sessions that took place after the conference formally ended was in managing the toxicities associated with chimeric antigen receptor T cell (CAR-T) therapy.
OX40 could be an exciting new target in immune-oncology that could be combined with checkpoint inhibitors to improve the T cell response.
Reflections on Day 1 of the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC).
Day 1 of the SITC annual meeting started with two workshops on immunotherapy and combination therapy
This week sees the start of the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD. We’re excited to be attending this meeting for the first time.
There was a lot going on in lung, melanoma, renal and colorectal cancer in terms of immunotherapy in Madrid.
Merck announced their Breakthrough therapy designation for Keytruda in lung cancer this morning. What did we learn from the updated data for checkpoint inhibitors in NSCLC at ESMO that was different from ASCO?
Checkpoint inhibitors are looking very promising in advanced gastric cancer
Genentech and NewLink announced a deal to license an IDO inhibitor. What's the impact of this on the IO pipeline?
Posters on new cancer drugs in development with novel targets were presented at ESMO 2014 Congress in Madrid.
Advances in Metastatic Colorectal Cancer may come from new druggable targets according to ESMO 2014 CRC Symposium
How is the ALK+ lung cancer market developing now that there are multiple next generation competitors following on from Xalkori and Zykadia? Check out our analysis of the developing landscape...
At ESMO 2014 Mary-Ellen Taplin, MD (Dana-Farber Cancer Institute) presented the results of the Tokai Pharmaceuticals ARMOR2 clinical trial of galeterone in men with advanced prostate cancer.
Day 3 of the live blog from the ESMO 2014 Cancer Congress in Madrid.
Day 2 Live Blog with news and commentary on what's taking place at the ESMO Cancer Congress in Madrid
ESMO 2014 Cancer Congress data starts to roll out today - throughout the day we'll be updating the blog with initial impressions of data as it's presented.
Most of the abstracts for oral presentations at the forthcoming ESMO cancer congress in Madrid have just been released. This is a preview of some that caught my attention.
There are some interesting science symposia at #ESMO14 in both immunotherapy and targeted therapies. We review what the hot topics are here.
A review of the key poster and poster discussion abstracts on immunotherapy and targeted therapies at ESMO 2014
Update on what to watch out for in immunotherapy at ESMO 2014.
Preview of some important breast cancer trials being presented in Madrid at #ESMO14.
With the recent FDA approval of Pembrolizumab (Keytruda) we can expect melanoma to be a hot topic at ESMO 2014.
Preview of Prostate Cancer oral presentations at ESMO 2014 Cancer Congress in Madrid.
To get more cancer therapies to the right patients faster, we need to find better surrogate markers or biomarkers of response that are inextricably linked to survival.
Amgen's phase III FOCUS trial of carfilzomib (Kyprolis) in relapsed/refractory multiple myeloma failed to meet its primary endpoint of overall survival.
Tokai Pharmaceuticals ($TKAI) have filed plans for a $75M IPO, largely based on the potential of their phase 2 prostate cancer compound, galeterone. What is the prostate cancer market opportunity for $TKAI?
Amgen announced the results of the phase III ASPIRE clinical trial for Kyprolis. What impact will this data have on the multiple myeloma landscape?
New CLL therapies that stand out in a rapidly changing CLL landscape include obinutuzumab (Gazyva), ibrutinib (Imbruvica) idelalisib (Zydelig), ABT-199/GDC-0199 and CTL019.
How will we decide which therapies to give patients with metastatic melanoma once the new immunotherapies are available?
There are a number of new targets, therapies and approaches in AML being investigated but which ones look most promising in this challenging landscape?
After a few setbacks in clinical development, some solid data is emerging with AbbVie/Genentech's ABT-199/GDC-0199 in CLL. Some more mature data at ASCO was very encouraging...
Diffuse large B cell lymphomas (DLBCL) are an aggressive subset of non-Hodgkins lymphomas that generally have a poor prognosis and a high unmet medical need. There is a raft of promising new therapies being evaluated for treatment.
Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.
Initial phase 2 data for Amgen's blinatumomab in B cell ALL looked encouraging 2 years ago but has it held up over time?
Several new agents in development emerged for the treatment of aggressive NHL (DLBCL and FL), including SGN-CD19A, polatuzumab vedotin and pinatuzumab vedotin.
A review of poster data at ASCO 2014 for new drugs from new cancer drugs from $CLDX, $OMED & NuCana BioMed.
Selection of some of the many posters that caught our attention. Companies whose products are mentioned include: $EXEL, $RHHBY, $XLRN, $MRK
After it's successful IPO, what are some of the challenges and opportunities facing Kite Pharma and their CAR-T cell immunotherapy?
AstraZeneca showed impressive data at ASCO 2014 for MEDI4736, a new anti PD-L1 immunotherapy.
There have been no new therapies in urothelial bladder cancer for 30 years - until now...
PD-1 antibodies nivolumab and pembrolizumab show considerable promise in metastatic melanoma. At ASCO 2014 we learnt more about how they compare against each other and their potential as a backbone for combinations.
What does the ASCO 2014 data show when you combine checkpoint inhibitors nivolumab and ipilimumab?
With the intense focus on immino-oncology, are targeted agents passe now?
A predictive biomarker for resistance to treatment by enzalutamide and abiraterone may lead to new prostate cancer drug development opportunities.
Final day at ASCO 2014 - what are the diehards listening to this morning?
Live blog with commentary on Day 4 of the ASCO 2014 annual meeting in Chicago.
Live blog with updates from Day 3 at ASCO 2014
Live Blog from Day 2 of ASCO 2014 in Chicago.
Coverage of day 1 at ASCO 2014 with commentary on some of the poster highlights.
Update on the top drugs in CLL including ibrutinib, obinutuzumab, idelalisib, ABT-199, GS-9973, ONO-4059, CTL019, TAK659, IPI-145, cerdulatinib and others.
Highlights in multiple myeloma at ASCO include drugs with a different mechanism of action eg panobinostat, daratumumab and elotuzumab, #ASCO14
Medivation and Astellas provided an update at AUA 2014 on the Xtandi PREVAIL data with a breakdown for visceral and non-visceral disease.
New targets are emerging in advanced prostate cancer that may help improve outcomes and overcome adaptive resistance
How we could overcome resistance to BRAF inhibitors in colon cancer with a triple combination approach
Can we improve responses to Zelboraf in advanced melanoma? The answer is a startling yes.
Insights on checkpoint inhibitors, co-stimulants, CAR T cell therapy and bispecific antibody TCRs
Update on emerging potential immuno-oncology biomarkers and combinations from AACR
Overcoming acquired resistance to therapy is a major focus in lung and prostate cancers. Check out the new developments from AACR.
Exciting new data was seen at AACR this year, including a novel ADC with a new target in melanoma, a metabolic target and understanding adaptive resistance to PI3K in breast cancer.
After disappointing results from FGFR inhibitors brivanib and dovitinib, can the next generation compounds overcome scepticism and offer better efficacy?
Immunotherapy is coming of age despite the chequered history in the past with vaccines. In part 1 we explore the state of play in lung cancer.
Understanding the regulatory circuitry that controls cell state and differentiation may turn out to be groundbreaking research that changes the way we think about targeting and treating cancer.
Pfizer's palbociclib showed promising survival data at the AACR annual meeting this weekend, but is it enough to garner approval on the basis of the phase II data?
This weekend at AACR a controversy emerged on the safety of Juno's CAR T cell therapy.
A review of innate immunotherapies including CD47, KIR, MICA and anti-glucan data at AACR in San Diego.
What are the new targets and drug combinations that are emerging in triple negative breast cancer (TNBC)? find out more about the promising developments in this field.
Review of some interesting cancer pipeline drugs at AACR 2014 including TKIs and ADC therapies.
Following on from yesterday’s post on the potential for small basket trials in ER+ breast cancer with…
Today brings the launch of our series on the AACR annual meeting Previews. A variety of different…
What new clinical approaches are being investigated to overcome resistance in melanoma?
Cell cycle inhibitors have been shown to have utility in cancer treatment. A new subclass is emerging to target CDK4/6 with more specificity and less toxicity.
Puma Biotech are expected to present the neoadjuvant data from ISPY2 for their pan HER inhibitor, neratinib, so what's the deal?
Dr Debu Tripathy presented one of the highlights of the MBCC conference - how we can use genomics to improve clinical trials in TNBC and MBC.
Can therapy for advanced breast cancer be individualized using proteomics and genomics data?
Much has been written about CAR T cells in B cell leukemias, but what about B cell lymphomas? Kite and the NCI had the honour of being the first to present data from ASH on their therapy in refractory DLBCL lymphomas
Nearly 4 years on from the original phase 2 data at ESMO, and we learn that MetMab (onartuzumab) did not meet it's endpoint in the interim analysis of lung cancer patients with MET expression.
There has been much debate about the cardiovascular risks associated with proteasome inhibitors in multiple myeloma, but what does the data show? A synopsis of the ASH 2013 data and what we can learn in the future...
The new race to market in advanced prostate cancer is in the M0 asymptomatic space. Several AR antagonists are competing to run trials here but will they lead to men living longer or not?
ASCO GU saw an update on the ipilimumab study in post chemotherapy CRPC. New biomarker data published this week in melanoma may be potentially useful in prostate and other tumour types.
Update on progress with anti-PD1 and PD-L1 immunotherapies in renal cell cancer. Where is the field going in this space?
Cross resistance between enzalutamide and abiraterone means that new prostate cancer drugs and targets are needed.
At ASCO GU 2014 Tokai Pharmaceuticals report data for the ARMOR2 trial with reformulated galeterone (TOK-001) in men with prostate cancer. Is this drug likely to make it to market?
Enzalutamide significantly decreases the risk of death and delays progression in the PREVAIL trial
At ASCO GU this week, the clinical data will be presented for the Medivation/Astellas PREVAIL phase III clinical trial of enzalutamide (Xtandi) in men with advanced prostate cancer prior to chemotherapy. The results of this trial not only have important commercial implications for Medivation/Astellas but for competitors in the prostate cancer market.
Roche Genentech are developing their anti-PD-L1 as both monotherapy and also in combination with targeted therapies in lung, melanoma, renal and colon cancers. How is the early development progressing?
“We are at beginning of a REVOLUTION in immunotherapy,” said Elizabeth M. Jaffee, MD at the start of American Society of Clinical Oncology GastroIntestinal (ASCO GI) symposium keynote lecture on Immunologic Treatments for GI Cancers.
Update from JP Morgan Healthcare 2014 on Clovis Oncology and AstraZeneca race to market with new drugs for treatment of T790M positive non-small cell lung cancer.
Agios Pharmaceuticals is focused on developing new therapies that target mutations in cancer metabolism, including IDH 1 and 2 for AML and Glioblastoma. Will they be successful despite the huge complexity involved in the underlying processes?
UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies. At ASH, the impressive data from adult and pediatric ALL was presented. This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.
Increasingly, we are seeing the evolution of diagnostic tests in cancer research. Foundation Medicine are using their gene sequencing platform to identify actionable mutations and assist oncologists make better treatment decisions for their patients.
Immunotherapy continues to be a hot topic in oncology with anti-PD-1 and other new approaches being discussed at the AACR-IASLC meeting in San Diego
The share price of Exelixis ($EXEL) is starting a run-up (after months in the doldrums) in advance of anticipated results from the COMET-1 phase 3 trial in metastatic castrate resistant prostate cancer (mCRPC) for cabozantinib (Cometriq, formerly XL184). Cabozantinib has been shown to significantly improve bone scans and decrease pain, but will it show an improvement in OS?
Start-up Juno Therapeutics is now in control of a legal dispute between St Jude Children’s Hospital and the University of Pennsylvania over chimeric antigen receptor (CAR) T cells intellectual property that contributed to the development of CTL019 licensed by Penn to Novartis. Penn are seeking to invalidate a St Jude patent that if upheld, CTL019 may infringe.
Preview of some of the key data being presented at ASCO GI in San Francisco this month.
ASCO GU symposium takes place at the San Francisco Marriott Marquis from Jan 20 – February 1, 2014. This preview discusses data to be presented on enzalutamide (Xtandi), abiraterone (Zytiga), ODM-201, ARN-509, ipilimumab (Yervoy).
There are some 5,000 abstarcts at ASH, many of them posters - what were the interesting nuggets this year?
BTK inhibition in the B cell receptor (BCR) pathway has been an exciting area of development over the last couple of years. What do the new competitors entering this space look like?
There was a wealth of new data in CLL at ASH but which companies or drugs were the winners and losers in New Orleans? Find out...
Juno Therapeutics is a start-up company with a mission to revolutionize the treatment of blood cancers through the use of chimeric antigen receptor (CAR) modified T cell therapy. The company recently launched with $120 million of series A funding. One of the scientific founders is Renier Brentjens MD, PhD, the Director of Cell Therapeutics at the Memorial Sloan-Kettering Cancer Center in NYC. He kindly gave an interview while at the ASH annual meeting in New Orleans.
The first readout from the I-SPY2 neoadjuvant breast cancer trial comes from the veliparib (PARP) arm.
Immuno-oncology is a hot topic at the moment and many new targets are emerging that may be useful in combination. This post discusses Innate Pharma's anti-KIR program in hematologic malignancies.
A preview of some of the landmark trial data emerging from the 2013 San Antonio Breast Cancer Symposium
One of the most interesting oral sessions at ASH 2013 took place on the last day and featured data on novel treatments for CLL. Data was presented on ABT-199, dinaciclib and the CAR-modified T-cell therapies in development by Novartis & Juno Therapeutics.
At ASH 2013 data on novel agents for the treatment of lymphoma was presented. This post discusses data for idelalisib in iNHL, SAR245409 in R/R Follicular Lymphoma and BAY-BAY 80-6946 (copanlisib).
ABT-199 has activity in CLL, but what about other tumor types? Check out this post to find out about a new target with potential.
With many new therapies emerging for the treatment of CLL, what criteria can physicians use to decide which therapy to give a patient?
Novartis announced this morning that their novel pan-HDAC inhibitor, panobinostat (LBH589) in combination with bortezomib (Velcade) and dexamethasone significantly prolonged progression-free survival (PFS) of patients with Multiple Myeloma in the phase III PANORAMA-1 trial.
Will the B cell signaling drugs work in NHL as well as CLL? What of Adcetris in front-line HL?
Chimeric Antigen Receptor T cell technology (CART) is an exciting new area, especially in hematologic malignancies. With the formation of a new start-up in Seattle, Juno Therapeutics, things just got very interesting...
A review of the upcoming CLL data from the American Society of Hematology ASH meeting.
Comprehensive preview of the new developments in multiple myeloma from ASH 2013.
FDA Office of New Drugs Director John Jenkins discusses the benefits of the Breakthrough Therapy designation and some of the challenges the agency faces in administering it.
John K. Jenkins, MD, Director of the Office of New Drugs, Center for Drug Evaluation and Research at the FDA offers a senior management perspective on what is a breakthrough?
A lot of companies are presenting myelofibrosis data at this year's ASH annual meeting in New Orleans. This preview discusses abstracts for ruxolitinib, INCB039110, momelotinib, fedratinib, BMS-91143, pacritinib, LY2784544, pomalidomide, sonidegib.
The huge wealth of research at the AACR-NCI-EORTC Boston conference provided a great learning environment of where future research with TKIs is likely to be heading...
The cancer landscape is rapidly changing, in more ways than people realise. Diagnostics are also of increasing importance in helping to decide which therapies patients should receive to optimize treatment.
An interview with Dr Deepak Sampath from Genentech on the rational for combining obinutuzumab (GA101) with GDC-0199 (ABT-199) for the treatment of B-cell hematological malignancies such as CLL & non Hodgkin’s lymphoma (NHL).
Data presented at the World Lung Cancer conference in Sydney suggests AstraZeneca AZD9291 is now ahead of Clovis Oncology CO-1686 in the race to bring a third-generation epidermal growth factor receptor (EGFR) inhibitor to market that targets the T790M resistance mutation.
An update on checkpoint inhibitors and CART from the AACR-NCI-EORTC Molecular Targets meeting - a lot of exciting possibilities are emerging!
Following the FDA approval of Abraxane, MLN0264, a novel ADC targeting GCC, may no longer have potential as a therapeutic in pancreatic cancer.
At the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics conference, Susan Galbraith, M.D, Ph.D. Head of the Oncology Innovative Medicines Unit at AstraZeneca discussed the rapid development of AZD9291, a potent and selective third-generation EGFR inhibitor.
Preclinical data for PF-06463922 (Pfizer), a next generation ALK inhibitor, with potency for all known Crizotinib ALK resistant mutants and ability to cross the blood brain barrier was presented today at the 2013 International Conference on Molecular Targets and Cancer Therapeutics in Boston.
Preview of some of the interesting non-embargoed abstracts from the ACCR-NCI-EORTC Molecular Targets conference in Boston
Update on ALK (alectinib), PD-L1 (MEDI4736), PI3K (GDC-0980 and BKM120) and MEK (trametinib) inhibitors in solid tumours
The latest data on BioMarin's PARP inhibitor BMN 673 in breast and ovarian cancer from ECCO 2013
Promising preliminary phase 1 data for AstraZeneca’s AZD9291 in T790M+ NSCLC presented today at the European Cancer Congress (ECCO 2013) is good news for lung cancer patients.
At ECCO 2013 in Amsterdam, positive data was presented from the phase 1/2 clinical trial for ODM-201 (Orion) a second generation AR antagonist. In contrast the data for ASP9521 (Astellas), a novel androgen biosynthesis inhibitor was negative.
Update on ipilimumab, AP26113, T-DM1, everolimus and others from Day 1 at the 2013 ECCO meeting in Amsterdam.
Review of the key abstracts in EML4-ALK lung cancer abstracts being presented at ECCO 2013 in Amsterdam.
A quick review of the check point immunotherapy abstracts from #ECC2013 in Amsterdam.
Overview of anti-PD-1 and PD-L1 immunotherapies plus ASCO 2013 data in melanoma and lung cancer.
Earlier this month, Janssen/Pharmacyclics announced they had submitted a New Drug Application (NDA) for FDA approval of ibrutinib, an oral Bruton’s tyrosine kinase inhibitor (BTK) in chronic lymphocytic leukemia (CLL) for the treatment of patients with a deletion of the short arm of chromosome 17 (del17p). Approval later this year or in early 2014 is highly likely given that ibrutinib has already been designated a Breakthrough Therapy by the FDA.
Takeda’s orteronel (formerly known as TAK-700) may be on its way to “dog drug heaven” after an interim analysis of the ECM-PC 5 phase 3 clinical trial showed that men with advanced prostate cancer taking the drug did not live significantly longer (HR 0.894, p=0.226) than those taking an inactive placebo.
Johnson & Johnson (JNJ) just announced the acquisition of privately-held Aragon Pharmaceuticals and the rights to ARN-509 a second-generation androgen receptor antagonist that will be a future competitor to Medivation’s Xtandi.
At ASCO 2013 the phase III MPACT trial data for Abraxane in pancreatic cancer was presented. This data was first reported at ASCO GI earlier this year. Abraxane in pancreatic cancer is a welcome new treatment option but it is not a major breakthrough that offers a dramatic shift in outcome.
At ASCO 2013, there was a lot of interest in a poster on Pfizer's PF-05280014, a potential biosimilar to Herceptin.
New clinical data on ibrutinib, obinutuzumab, idelalisib, IPI-145, ABT-199 for the treatment of Chronic Lymphocytic Leukemia (CLL) will be presented at ASCO 2013.
The poster sessions at the 2013 annual meeting of the American Association for Cancer Research (AACR) are not all about mice, and test tubes, but offer insights into biotech drug development, new targets and licensing opportunities.
My overriding impression of large cap Pharma R&D from the 2013 annual meeting of the American Association for Cancer Research (AACR) was that Novartis and Genentech remain the front-runners in cancer drug development, with Pfizer very much up and coming.
GDC-0032 is a next generation PI3K inhibitor that spares the beta-isoform of PI3K. Genentech hypothesize this may reduce some of the undesired side effects such as effects on metabolism, previously seen with pan PI3K inhibitors such as GDC-0941. At AACR 2013 promising early clinical data was presented for GDC-0032 in PI3KCA mutant cancers, especially breast cancer.
AACR 2013: A late-breaking clinical trial presentation to watch is LB-290: Targeting MUC16 with the Antibody-Drug Conjugate DMUC5754A in patients with platinum-resistant ovarian cancer. This data will be presented by Joyce Liu, MD, MPH from Dana-Farber Cancer Institute in the Clinical Trials Symposium on Tuesday, Apr 9 at 4.00 pm.
Tokai Pharmaceuticals have yet to show the new formulation of galeterone is safe and effective or that men with advanced prostate cancer live longer when taking the drug compared to taking abiraterone or enzalutamide either sequentially, or in combination. While galeterone may offer an innovative mechanism of action, it is too early to say what potential it may have in the treatment of advanced prostate cancer.
ASCO GU 2013: dasatinib phase 3 clinical trial fails to show any survival benefit in men with advanced prostate cancer when used in combination with docetaxel chemotherapy. However whether there are a subset of advanced prostate cancer patients who might respond to the bone-targeted effects of the drug remains open to question.
At the ASCO GU 2013 meeting in Orlando, Bristol Myers Squibb will publish the results of the dasatinib (Sprycel) phase 3 prostate cancer trial. New data on abiraterone, alpharadin, ARN-509 and enzalutamide is also expected.
For many attendees, the most exciting news at the 2012 annual meeting of the American Society of Hematology (ASH) held last December in Atlanta was the prospect of personalized T cell therapy for the treatment of patients with B cell cancers such as chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).
ABT-199 is an exciting new agent in development with potential as a new treatment option for CLL & MCL. It is a potent and selective BCL-2 inhibitor that has been engineered not to cause the dose-dependent thrombocytopenia seen with navitoclax.
Medivation investors hoping for a windfall will be disappointed to hear that on December 20, 2012 a California judge ruled the company had no rights to what is now known as Aragon Pharmaceuticals ARN-509, a next-generation androgen receptor (AR) antagonist for advanced prostate cancer, similar in chemical structure to enzalutamide (Xtandi)
Dr Hagop Kantarjian from The MD Anderson Cancer in Houston discussed chronic myeloid leukemia (CML) treatment options at the 2012 Chemotherapy Foundation Symposium in New York.
AB Science has filed for European approval of mastinib in pancreatic cancer with the European Medicines Agency based on data that showed masitinib significantly increased survival in a subset of patients with a novel genetic biomarker. Data will be presented at 2013 ASCO GI symposium.
ODM-201 is a second generation androgen-receptor AR antagonist from Orion Pharma in early stages of clinical development.
Results were presented at ESMO 2012 for the TH-CR-404 phase 2 clinical trial that compared the efficacy and safety of TH-302 (Threshold Pharmaceuticals) plus gemicitabine versus gemcitabine alone in patients with untreated advanced pancreatic cancer.
One of the late-breaking abstracts that I am looking forward at the forthcoming annual Congress of the European Society for Medical Oncology (ESMO 2012) in Vienna is on ODM-201, a new prostate cancer drug from Orion Pharma.
FDA approves first artificial retina prosthesis, the Argus II from Second Sight. This is not a bionic eye. To date, only crude images can be detected. There is no dramatic restoration of sight or vision, instead retinal prostheses currently only offer the ability to detect light and large shapes. Several companies and research groups including Bionic Vision Australia are working on innovative retinal prostheses that aim to restore some vision.
Swedish researchers describe how a panel of five cerebrospinal fluid (CSF) biomarkers allowed the differential diagnosis of common dementia from Parkinsonian disorders.
Biomarkers can be used for diagnosis and for monitoring the safety and effectiveness of treatments. They are increasingly becoming important in the selection of patients for clinical trials, and as potential surrogates for clinical endpoints that may take a long time to occur e.g. measuring how long someone will live in a cancer trial (overall survival).
Detecting thyroid cancer early and avoiding unnecessary surgery is the potential promise of a new diagnostic test.
A diagnosis of stage IV pancreatic cancer is pretty much a death sentence. There is, therefore, an unmet need for effective new pancreatic cancer treatments.
Piramal Healthcare presented posters on early-stage drug development compounds, including: P7170, a Phosphoinositide 3-Kinase (PI3K)-mammalian Target of Rapamycin (mTOR) and Activin Receptor-Like Kinase 1 (ALK1) inhibitor & P2745, an orally bioavailable molecule effective in imatinib resistant chronic myeloid leukemia cell lines including those with the T315i mutation.
ABT-199, a potent and selective inhibitor of Bcl-2. Steven Elmore from Abbott Laboratories presented impressive early data from an ongoing phase I trial in patients with chronic lymphocytic leukemia (CLL).
Dr Hussain discusses the scientific rationale behind the mechanism of action for cabozantinib, a multi-kinase inhibitor of C-MET, VEGF and others.
At the 2011 ASCO annual meeting, Dr Hussain presented data from a non-randomized phase 2 trial with cabozantinib that showed dramatic improvements in bone scans before and after treatment.
"My average patient is interested in living longer, not just in controlling their pain." Dr Maha Hussain
Orteronel (TAK-700) is a selective, non-steroidal inhibitor of 17, 20 lyase, a key enzyme involved in the production of androgens such as testosterone. This is a similar mode of action to abiraterone acetate (Zytiga).
radium-223 in bone-metastatic castration resistant prostate cancer patients (CRPC), not only significantly prolonged time to first skeletal related event (SRE), but significantly prolonged 3 out of the 4 SRE components.
Low-level expression of micro RNA-375 (miR-375) correlated with poor outcome in tumors of HNSCC patients.
My preview of prostate cancer abstracts that caught my attention.
The South Korean equivalent of the FDA have approved radotinib (Il-Yang pharmaceuticals) or chronic myeloid leukemia (CML).
